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MEGHAN KATHLEEN GRANDAL. Venomics as a Drug Discovery Platform: Identifying
Conopeptides with Pharmacological Activity. (Under the direction of FRANK MARÍ).

ABSTRACT

Cone snail venom is a mixture of disulfide-constrained peptides (conotoxins),
hormone-like peptides, and proteins that have been ‘weaponized’ for predation and
defense. Venom peptides, or conopeptides, have efficiently evolved to bind receptors and
ion channels that modulate the neuromuscular, cardiovascular, and central nervous
systems in prey species. With over 850 species of cone snails, each with unique venom
concoctions, cone snail venom is a valuable source of novel pharmacological probes and
potential drug leads. However, the complexity of the venom poses a challenge for drug
discovery. Contributing to the complexity is 1) a wide range in molecular weight 2) peptide
hyper-variability by post-translational modifications and 3) many potential molecular
targets to pursue. In this research, a ‘venomics’ approach was employed for the global
identification of venom components. This ‘venomics’ methodology combines RNAseq data
from the venom duct and proteomic data from raw injected venom to identify novel
conopeptides.
This project was a data-driven effort to define the venom components of the cone
snail, Conus purpurascens, and to stimulate further hypothesis-driven studies. First, 21
new base conopeptides were identified from the injected venom of Conus purpurascens,
a fish-hunting cone snail native to the Pacific coast of Central America. The molecular
targets were projected based on homology to previously characterized conopeptides. The
newly identified conopeptides included α-conotoxin, α-PID. Alpha-conotoxins are
inhibitory ligands of nicotinic acetylcholine receptors (nAChRs), and the most ubiquitous
venom components across the Conus genus. Ligands of nAChRs are clinically important
for addiction, cognitive disorders, neurodegenerative diseases, and pain. Functional
characterization of α-PID and three other α-conotoxins was performed to test their activity
on different nAChR subtypes using heterologous receptor expression and molecular
modeling techniques. A unique insulin-like peptide (Con-Ins P1) was also identified and
was the first instance of an insulin-like peptide identified directly from injected venom. This
research demonstrates how discovery-based ‘venomics’ workflows can be used to yield
novel peptides with pharmacological applications and stimulate further hypothesis-driven
experiments.
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CHAPTER 1:
INTRODUCTION AND SIGNIFICANCE
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1.1

Venom in drug discovery
The world’s most poisonous animals, which include snakes, scorpions, jellyfish, octopi,

and cone snails, all use venom for predation and defense. Venom is a complex mixture of
peptides and proteins that have evolved across the animal kingdom. While envenomation
strategies may differ across clades, the venom protein scaffolds are highly conserved for
the unified goal of paralyzing prey. Venom peptides and proteins target a wide range of
pharmacological targets to accomplish this goal, and because of this, humans continue to
use and study venom for medicinal purposes [2]. There are a few drugs on the market
derived from venom that fall under the following therapeutic categories: ACE inhibitors
(captopril), anti-platelet drugs (eptifibatide and tirofiban), thrombin inhibitors (lepirudin and
bivalirudin), type-2 diabetes drugs (exenatide), and pain killers (ziconotide) [3].
Chlorotoxin from the deathstalker scorpion, Quinquestriatus hebraeus, binds chloride
channels with high affinity. Chlorotoxin has unique selectivity for tumor cells, and when
attached to a fluorescent dye (Tumor Paint®, Blaze Biotech, Seattle) allows surgeons to
visualize tumors using infrared glasses [4]. Tumor Paint® is currently undergoing clinical
trials for use during surgical removal of brain, breast, and skin cancers. Dalazatide (Kineta,
Seattle), a voltage-gated potassium channel blocker (Kv1.3) from the Caribbean sun
anemone (Stichodactyla helianthus), is currently being developed for the treatment of
autoimmune diseases. Phase I trials showed positive results against psoriasis [5] and is
now being tested for rheumatoid arthritis, lupus, and type 1 diabetes. There are also
several venom peptides in preclinical development for pain, including tarantula-derived
sodium channel blockers (Nav1.7) [6] and conotoxin RgIA [7]. Therapeutic applications of
conotoxins will be discussed in-depth in the following section.
The biggest obstacle when developing venom components as drugs is their
bioavailability. This results from their relatively large size, compared to small molecule
therapeutics, and their hydrophilic nature, rendering them incapable of crossing biological
2

membranes to reach their molecular targets. These barriers include the blood-brain barrier
and intestinal walls [2, 8]. Venom toxins under drug development commonly require
peptide engineering to improve bioavailability. One successful mechanism is the
cyclization of conotoxins by linking the N- and C- termini [9-11]. Another option is to
synthesize smaller toxin analogs that maintain the functional group of the peptide but
improve bioavailability. Post-translational modifications (PTMs), such as glycosylation,
have also been shown to improve peptide permeability through biological membranes [12].
One group of peptides that have had success as pharmaceutics are the cysteine knot
peptides, miniprotein scaffolds restrained by multiple disulfide bonds [13]. Included in this
family are the knottins, which have six cysteine residues
and a specific disulfide pairing between cysteines 1 and
4, 2 and 5, and 3 and 6 (Figure 1). Cysteine knot peptides
are naturally produced by animals, plants, and fungi, but
the knottins are found most prominently in cone snail and
spider venom [14]. More recently, knottin peptides have
Figure 1- Knottin peptide
structure and disulfide pairing.
Adapted from Kintzing et al. 2016

also been described from anemone venom and
marine sponge tissue [15, 16].
Two FDA approved drugs are derived from

naturally occurring cysteine knot peptides, linaclotide (Linzess®, AbbVie and Ironwood
Pharmaceuticals, Inc.) from the endogenous hormone guanylin [17] and ziconotide
(Prialt®, TerSera Therapeutics, LLC) from conotoxin ω-MVIIA [18]. Factors contributing to
cystine knot peptide success as drugs include their thermal, chemical, and proteolytic
stability [19]. Their resistance to proteases allows these peptides to remain intact in
biological environments, including the gastrointestinal tract, thereby increasing their
bioavailability and likelihood of availability through oral administration [20]. This is not the
case for ziconotide, a conotoxin-based drug for chronic pain that is administered
3

intrathecally through an infusion pump due to its low oral bioavailability. As we continue to
discover venom peptides with clinically relevant targets, the knottin miniprotein scaffolds
will require substantial engineering efforts and improved drug delivery mechanisms.
1.2

Conopeptides and their therapeutic applications
Conopeptides are a diverse group of rapidly evolving gene products found in cone

snail venom that range in size, structure, and molecular target. They work synergistically
to immobilize prey/predators. Positive selection through point mutations, alternative
splicing, and post-translational modifications (PTMs) has created a rich source of bioactive
peptides that target membrane receptors with high specificity [21-23]. The molecular
targets are used to classify the conopeptides into pharmacological families (Table 1) [24,
25]. Their targets include voltage-gated and ligand-gated ion channels, G-protein-coupled
receptors, and neurotransmitter transporters, all with important clinical implications.
Several conopeptides have successfully reached clinical trials (Table 2). Although
conopeptides have a broad range of therapeutic targets, their high specificity for neuronal
receptors make them particularly apt for pain treatment [26, 27]. Overuse and
overprescribing of opiate-based pain killers have resulted in a current opiate crisis [28].
There is a severe need for alternative, non-opiate pain management treatments.
Conopeptides are a promising source of novel pain medications without the risk of
addiction and other negative side effects caused by opiate use.
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Table 3- Molecular targets and bioactivity of known Conopeptides.
Pharmacological Family
α- conotoxin

Target

αA- conotoxin
αS- conotoxin
αD- conotoxin
Ψ- conotoxin
σ- conotoxin
μ- conotoxin
μO- conotoxin
δ- conotoxin
ω- conotoxin
κA- conotoxin
κJ- conotoxin
κM- conotoxin
κO- conotoxin
χ- conotoxin
Conantokin
Contulakin
Conopressin
conoCAPS

nAChR

5HT3R
Na+ channel
Ca2+ channel
K+ channel
shaker K+
NE transporter
NMDA receptor
Neurotensin receptor
Vasopressin receptor

Activity

Framework
I
II
IV
VIII
XX
III
VIII
III
VI/VII
VI/VII
VI/VII
IV
XIV
III
VI/VII
I/X

inhibit channel

allosteric inhibitor
inhibit channel
inhibit channel
inhibit conductance
delay inactivation
inhibit channel
inhibit conductance
inhibit channel
inhibit channel
inhibit transporter
--Agonist
Agonist
cardioactive peptide

Cysteine pattern
CC-C-C
CCC-C-C-C
CC-C-C-C-C
C-C-C-C-C-C-C-C-C-C
C-CC-C-CC-C-C-C-C
CC-C-C-CC
C-C-C-C-C-C-C-C-C-C
CC-C-C-CC
C-C-CC-C-C
C-C-CC-C-C
C-C-CC-C-C
CC-C-C-C-C
C-C-C-C
CC-C-C-CC
C-C-CC-C-C
CC-C-C

C-C
C-C
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Table 4- Conopeptides that reached human clinical trial as pain therapies.
Conopeptide
MVIIA

Species
C. magus

Target
Cav2.2

Application
Pain

CBID
MrIA

C. catus
C. marmoreus

Pain
Pain

Contulakin-G
Conantokin-G
Vc1.1
RgIA4

C. geographus
C. geographus
C. victoriae
C. regius

Cav2.2
Norepinephrine
transporter
Neurotensin receptor
NMDA receptor
α9α10 nAChR
α9α10 nAChR

Status
FDA approved,
2004
discontinued
discontinued

Pain
Pain, epilepsy
Pain
Pain

discontinued
discontinued
discontinued
preclinical

Thus far, Ziconotide is the only conotoxin-derived drug approved by the FDA (PrialtTM)
and is the only venom peptide approved for the management of intractable pain.
Ziconotide is a non-opioid, non-NSAID analgesic that blocks CaV2.2 subtype calcium
channels [29]. It was developed from the conotoxin MVIIA from Conus magus. Ziconotide
requires an intrathecal drug delivery system because of its inability to pass the blood-brain
barrier and is therefore not an optimal alternative for chronic pain management.
Contulakin-G, a neurotensin receptor antagonist from Conus geographus, was tested
previously in a clinical trial for severe chronic pain. Vc1.1 from Conus victoriae, a nicotinic
receptor inhibitor, went to a Phase 2 clinical trial for neuropathic pain associated with
sciatica and diabetic neuropathy [30, 31]. Another nicotinic receptor inhibitor, RgIA4, an
analog of α-conotoxin RgIA from the venom of Conus regius, is currently in preclinical
development for neuropathic pain [3, 32]. Vc1.1 and RgIA both inhibit nicotinic receptors
[33], but conflicting evidence suggests that their analgesic effect is through the GABAB
receptor [34, 35]. In this proposed study, we aim to identify venom peptides that target
nicotinic receptors.
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1.3

Nicotinic acetylcholine receptors: structure and function
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels responsible

for neurotransmitter signaling at the synaptic gap and the neuromuscular junction. They
belong to the Cys-loop superfamily of ligand-gated ion channels, which includes receptors
gated by acetylcholine, serotonin, GABA, and glycine. All contain a signature cysteine loop
formed by a disulfide bond joining adjacent subunits [36, 37]. Initial studies on nAChRs
utilized the receptor-dense electrical organ tissue of Torpedo marmorata (electric stingray)
[38]. This later allowed cloning and functional characterization of seventeen different
genes for nAChR subunits (α1-10, β1-4, γ, δ, and ε). Any five of these subunits join to
form functional pentameric proteins that can be either heteromeric or homomeric.
Nicotinic receptors are classified into the muscle or neuronal subtypes depending on
their subunit composition and localization [39]. Muscle subtypes are comprised of α1, β1,
γ, δ, and ε subunits, and are expressed at the neuromuscular junction. The muscle-type
nAChRs are critical for skeletal muscle contraction and voluntary movement. Inhibitors of
muscle-type nAChRs include local anesthetics, such as lidocaine [40], and α-neurotoxins
that cause paralysis, such as the snake venom toxin, α-bungarotoxin [41]. Neuronal
subtypes are comprised of combinations of α and β subunits (α2-6 and β2-4) or are
homomeric (α7-10). Neuronal subtypes are heterogeneously expressed throughout the
central and peripheral nervous systems where they are involved in neuronal transmission
and the dopaminergic pathway [42].

7

The

ligand-binding

properties

of

nAChRs have been studied using the Xray

crystal

structure

of

the

soluble

acetylcholine binding protein (AChBP) of
mollusks Lymnaea stagnalis and Aplysia
californica [43]. AChBPs are not functional
ion channels, however; they form stable
homopentamers that preserve features of
the ligand-binding domain of nAChRs and
thereby serve as useful binding models.

Figure 2- Overlay of AChBP subunit with
muscle-type nAChR α-subunit. AChBP
subunit (blue) with muscle-type nAChR αsubunit (gray) (Hansen, 2005). N-terminal
(N), C-terminal (C), ligand-binding domain
(Loops B,C,F).

The ligand-binding pocket is ‘gated’ by a
loop structure (Loop C) that controls ligand
activity

[44].

Crystallized

AChBP

complexes with select nicotinic agonists and antagonists revealed that agonists bind
below the C loop causing it to close over the ligand-bound pocket and open the channel
pore. Antagonists, such as α-conotoxins, cause Loop C to be held in an extended
conformation away from the ligand-binding pocket [45, 46] (Figure 2). Heteromeric
receptors have two ligand-binding sites located between adjacent α and β subunits.
Homomeric receptors have five ligand-binding sites located between each α subunit [47].
Ligands of neuronal nAChR subtypes are clinically important as treatments for
addiction, cognitive disorders, neurodegenerative diseases, and pain [48]. However, there
are few compounds available that target neuronal subtype nAChRs with high selectivity.
To explore the physiological role of neuronal-type receptors, we need highly selective
pharmacological probes. Alpha-conotoxins are the first group of peptide α-neurotoxins that
show selectivity for neuronal subtype nAChRs and are therefore extremely valuable
research tools and pharmacological agents [49, 50].
8

1.4

Alpha-conotoxins: ligands of the nAChR
Alpha-conotoxins are inhibitors of the nAChR and are the most ubiquitous venom

components across the Conus genus. All species analyzed express one or more αconotoxins in their venom that work synergistically to paralyze prey. Unique from other
nAChR ligands, α-conotoxins exhibit remarkable subtype selectivity, specifically among
neuronal receptor subtypes
Alpha-conotoxins can display different cysteine frameworks, or patterns of cysteine
residues within a sequence (Table 1). Framework I α-conotoxins belong to the A
Superfamily, as defined by a conserved gene signal sequence. This is the largest group
of characterized α-conotoxins with the greatest diversity in subtype selectivity. The posttranslational modifications commonly found on these conotoxins (C-terminal amides and
hydroxyprolines) are important for peptide stability and bioactivity [51]. In our study, we
will be focusing on framework I α-conotoxins because of their relatively small size (<22
amino acids) and because of their well-established disulfide connectivity (C1-C3, C2-C4)
[52]. The fact that they have only two disulfide bonds with established pairing makes these
peptides good candidates for chemical synthesis, which is necessary to perform functional
assays.
Within the framework I α-conotoxins,
there is significant diversity in amino acid
composition and the size of the intercysteine loops. Inter-cysteine loop size
Figure 3- Alpha-conotoxin selectivity for
nAChR subtypes.

affects affinity toward either muscular or

neuronal nAChR subtypes (Figure 3) [53, 54]. In general, α-conotoxins exhibiting a 3/5
inter-cysteine loop pattern are inhibitors of neuromuscular junction subtypes, and 4/3 and
4/7 toxins inhibit neuronal subtypes [55]. To date, there are very few 4/4 α-conotoxins
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characterized. Of the ones known, α-BuIA inhibits neuronal receptors containing α3, α6,
and β2 subunits, whereas α-PIB and α-PIC preferentially inhibit muscle subtypes.
Neuronal nAChR subtypes are expressed heterogeneously throughout the central
nervous system [56] and are implicated in a range of neurological conditions (Figure 4).
The most widely expressed
subtype in the mammalian brain,
α4β2, is heavily involved in the
dopaminergic

pathway

and

nicotine addiction. This receptor
can exhibit different subtype
stoichiometry; (α4)2(β2)3 is more
Figure 4-Neuronal subtypes of nAChRs and their
clinical applications.

sensitive

to

nicotine

than

(α4)3(β2)2 [57]. Because of its

role in nicotine addiction, α4β2 is the clinical target for smoking cessation therapies,
including the partial agonist, varenicline (Chantix, Pfizer, Inc.). Very few α-conotoxins
inhibit α4β2, with α-GID being the most potent inhibitor. Amino acid substitution studies
on α-GID deemed A10, V13, and V18 as critical residues for α4β2 selectivity [58].
Of the neuronal subtypes, the α3β2 receptor is the most common α-conotoxin target.
LvIA is the first α3β2 subtype-selective conotoxin. The Asp11 residue is responsible for
selectivity over α6-containing subtypes [59]. The selectivity of α-PnIA for α3β2 over its
alternative α7 target is dependent on Ala10 [60].
The α3β4 subtype is the predominant nAChR in the sensory and autonomic ganglia
neurons. It is expressed in the mesolimbic dopamine circuitry of the midbrain where it
modulates addiction to nicotine and potentially other drugs of abuse [61, 62]. AuIB is an
α3β4 selective toxin with an uncommon 4/6 inter-cysteine loop size. The Phe9 residue
regulates subtype selectivity [63]. Ligands with α3β4 selectivity will help better understand
10

the role of these receptors in the midbrain and may be useful therapeutics for addiction
[64].
The α6-containing subtypes are also expressed abundantly in the midbrain
dopaminergic neurons and are mediators of the nicotine reward pathway [65, 66]. Ligands
with selectivity for α6-subtype nAChRs are important molecular probes to study the
pathophysiology of addiction and other dopamine-related disorders, such as Parkinson’s
disease. However, α6 selectivity is rare because of its high homology with the α3 subunit.
There is one α6-biased ligand, α-PIA from C. purpurascens, known thus far. α-PIA
preferentially inhibits α6-containing receptors with a 75-fold greater affinity than α3
receptors [67, 68]. α-MII from C. magus is an α3-selective ligand, but alanine substitution
studies distinguished α-MII analogs with significantly increased affinity α6 over α3 [69],
shedding light on structural determinants of α6 selectivity.
Homomeric α7 nAChRs are a unique subtype expressed throughout the brain and in
non-neuronal tissues, like immune cells [70]. Their distribution in the brain includes the
hippocampus and cerebral cortex involved in learning and memory [71]. The α7 receptor
is unique in that agonist binding elicits a relatively low ion current and becomes easily
desensitized, compared to heteromeric subtypes. The α7 receptors also bind highlyselective molecules called positive allosteric modulators (PAMs) that significantly enhance
agonist-induced ion currents, but have no effect alone (reviewed in [39]). Conotoxin αMrIC is the first described selective α7 agonist that can activate, rather than inhibit, α7
receptors in the presence of PAMs (65). It is thereby a useful tool in studying the kinetics
and function of this unique receptor subtype.
The α9 homomeric receptor is another unique, and perhaps the most elusive, nAChR
subtype. It is expressed in cochlear hair cells and periphery epithelial and immune cells
[42]. The α9 subunit can co-express with α10 to form functional ion channels, and elicit
ACh-evoked currents 100-fold stronger than homomeric α9 receptors [72]. Both α9 and
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α9α10 are thought to be involved in pain pathways [73]. The α-conotoxins Vc1.1 (4/7) and
RgIA (4/3) both elicit analgesia through inhibition of α9α10 nAChRs [32, 73]. As an
effective anti-nociceptive target, α9 nAChRs offer an alternate non-opioid pathway for pain
treatment that needs to be explored.
1.5

Impact
The identification of venom components has increased rapidly with the advancement

in next-generation sequencing technologies and bioinformatics tools. Venomics is the
hybridization of RNAseq and proteomic analysis to study venom and identify its
components. Venomics enables high-throughput discovery of venom peptide and protein
sequences [74-76].
Venomics methodology supersedes previous chemical-based or bioassay-guided
fractionation for natural product discovery. These traditional discovery methods require
multiple biological assays or elaborate chemical elucidation schemes to find a single
compound of interest. The workflow established in this proposed research project can be
modified to discover novel active peptides from any venomous animal. This project will
also provide information on novel α-conotoxin activity on multiple nAChR subtypes with
important clinical applications. Specifically, α-conotoxins have proven to be good
candidates for non-opiate pain treatment and have made it to clinical trials. To combat
our current opiate crisis and regulate the over-prescription of opiate medications, we must
have safe and effective alternatives for pain management.
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CHAPTER 2:
MATERIALS AND METHODS
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2.1

Cone snail specimens

2.1.1 C. purpurascens specimens and venom collection
Specimens of C. purpurascens (n = 27)
were collected from the Pacific coast of
Costa Rica. C. purpurascens was chosen
for

this

intraspecific

venom

analysis

because it is a fish-hunting species that
uses a hook-and-pull strategy to capture
prey allowing venom collection through a Figure 5- Venom milking from
C. purpurascens.
“milking” procedure [31]. Briefly, venom is
collected into Eppendorf tubes that have a piece of latex glove stretched over the opening
and are baited with a piece of goldfish fin on the latex. When the snail senses the fin, it
spears the latex and injects venom into the tube (Figure 5). After the venom is released,
the snail is fed with a live fish. Snails were kept in an aquarium facility where they were
fed and milked regularly. The injected venom samples were stored at -80 °C until used for
further analysis.
2.1.2 Other Conus species
Venom ducts were also dissected for downstream RNASeq from the following Conus
species: C. striatus, C. vanhyningi, C. brunneus, C. spurius, C. princeps, C. regius, C.
gladiator, C. lindae, C. arangoi, C. moreleti, C. nussatella, C. richardbinghami, C.
leopardus, C. caysalenensis, C. granulatus, C. dalli, C. anabathrum.
2.2

Tissue dissection and RNA sequencing
Venom ducts were dissected from two C. purpurascens snails, specimens 1 and 14.

The venom ducts were immediately placed in RNAlater (Invitrogen), and stored at -80° C.
mRNA was extracted from the venom duct using an RNeasy Lipid Tissue mini kit (Qiagen),
and mRNA quality was confirmed with a 2100 Bioanalyzer (Agilent). Illumina libraries were
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prepared with a NEBNext Ultra Directional RNA Library prep kit (New England BioLabs).
Sequencing was performed on a NextSeq 500 platform (Illumina, Inc.) and each venom
duct yielded approximately 28 million paired-end reads (75 bp).
2.3

Bioinformatics

2.3.1 Transcriptome assembly
Raw reads for each venom duct were assembled with Trinity de novo transcript
assembler (v. 2.2.0) using default parameters; group pairs distance: 500 bp, path
reinforcement distance: 75 bp [33]. The resulting transcriptomes (A and B) were translated
with EMBOSS applications, transeq (6-frame) and getorf (between start and stop codons)
[34, 35] (Table 3). Transcriptomes were interrogated for conotoxin expression.
2.3.2 Conopeptide interrogation
The Trinity de novo assemblies (transcriptomes A and B) were translated with transeq
and getorf, and resulting transcripts were blasted (blastp, e = 10-5) against the UniProt
Animal Toxin Annotation database (ToxProt) and all UniProt Conus entries (TaxID: 6490)
to extract toxin-like sequences. The resulting sequences were developed into databases
for proteomic searches (described in detail in Section 2.5). Transcript quantification (TPM)
for conopeptides from the C. purpurascens venom duct transcriptomes was performed
with Salmon [30] using the Trinity assembly as the reference transcriptome (kmer length
= 31).
2.3.3 Insulin-like peptide interrogation
The translated FASTA files were interrogated for conoinsulin sequences using
BLASTp search function (e= 10) with a conoinsulin query database that included all
conoinsulin sequences from UniProt. Transcript quantification (TPM) for conoinsulins from
C. purpurascens tissues was performed with Salmon [30] using the Trinity assembly as
the reference transcriptome (kmer length = 31).
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A phylogenetic analysis of ILPs was performed using insulin superfamily proteins
obtained from the InterPro database (IPR036438). Taxonomy IDs were extracted and
submitted to NCBI Taxonomy Browser- Common Tree to generate a phylip tree. The
phylip tree file was imported into Geneious 2020.1.1 (Biomatters, Ltd., Auckland, NZ) to
create a phylogenetic tree. ILPs from all Conus sp. were extracted from the InterPro
database (IPR036438) and aligned using Clustal omega within Geneious software.
2.4

Mass spectrometry analysis of venom samples
An aliquot of each venom sample (5 µL) was diluted in ammonium bicarbonate buffer

(50 mM). Cysteine bonds were reduced with dithiothreitol (7 mM) for 1 h at 60 °C and
alkylated with iodoacetamide (18 mM) for 1 h at 21 °C in the dark. Following reduction and
alkylation, the samples were desalted using C18 spin columns (ThermoFisher Pierce) and
lyophilized before LC-MS/MS analysis.
Samples were reconstituted in water/0.1% formic acid and analyzed by LC-MS/MS on
an Orbitrap Fusion Lumos trihybrid mass spectrometer (ThermoFisher Scientific) coupled
with an UltiMate 3000 RSLCnano System (ThermoFisher Scientific). A 160 min gradient
with solutions A (5% acetonitrile/ 0.1% formic acid) and B (80% acetonitrile/ 0.1% formic
acid) on an Acclaim PepMap 2μm C18 column (75 μm x 25 cm) (ThermoFisher Scientific)
was used. The flow rate was set at 0.3 μL/min with the following gradient steps: 0 min at
5% B, 10 min at 5% B, 115 min at 27.5% B, 130 min at 40% B, 140 min at 95% B, 150
min at 5% B, 160 min at 5% B.
MS1 scans (200-2000 m/z) were collected with an Orbitrap mass analyzer at a
resolution of 120,000 using quadrupole isolation; RF lens 30%, AGC target 4.0e5, and a
50 ms injection time. Precursor ions were fragmented using HCD (32%). MS2 scans were
collected with an Orbitrap resolution of 30,000 using quadrupole isolation and AGC target
2e4. A charge state filter was used (+2-6) and the intensity threshold was set to 2e4.
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Dynamic exclusion was set to exclude precursor ions for 60 s after collecting 10 MS2
scans within 30 s.
2.5

Database configuration and search parameters
Several databases were configured and assessed for completeness before choosing

the best search database for the 27 venom samples. The database was optimized for
time-intensive non-enzymatic searches with many PTMs using the following criteria;
inclusivity of conopeptide-encoding transcripts and the total number of entries. We
compared the following four database configurations, all from the de novo transcriptome
assemblies of venom duct RNAseq data. 1) The de novo assembly was blasted (blastX,
e = 10-5) against the UniProt Animal Toxin Annotation database (ToxProt) and all UniProt
Conus entries (TaxID: 6490), then translated ORFs were extracted with getorf, and
complete transcripts with signal sequences were extracted with SignalP v4.0 [77]. 2) The
de novo assembly was blasted as previously described using blastX, then the hits were
translated with transeq, and only transcripts containing > 4 cysteines were extracted. 3)
The de novo assembly was translated, the ORFs were extracted with getorf, and complete
transcripts with signal sequences were extracted with SignalP (this configuration did not
include a blast step). 4) Trinity assembly was translated with transeq and getorf, and
resulting transcripts were blasted (blastp, e = 10-5) against the ToxProt database to extract
toxin-like sequences. We chose the ToxProt-guided configuration (4) as the optimal
search database, to which we added a customized C. purpurascens database that
included conopeptide sequences not present in the transcriptomes (Table 3, Figure 6).
The additional C. purpurascens database included previously identified peptides from
UniProt (taxid: 41690) and unpublished conopeptide sequences identified in-house using
the PEAKS de novo search algorithm (Bioinformatics Solutions Inc., Ontario, Canada)
[78]. PEAKS can deduce peptide sequences from MS/MS spectra without a database.
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PEAKS scored the predicted sequences with an average local confidence (ALC) score. In
the in-house C. purpurascens database, only predicted conopeptide sequences with ALC
scores greater than 98% were included.
Database searches were performed with the Sequest algorithm within Proteome
Discoverer v2.0 (Thermo Fisher Scientific). Search parameters included a mass error of
10 ppm for precursor peptides and 0.02 Da for fragment ions. Fixed modification,
Carbamidomethyl (C), was introduced and several previously reported conotoxin PTMs
were introduced as variable modifications: oxidation (M/P), carboxylation (E), bromination
(W), deamidation (N/Q), pyroglutamate (N-terminus), and amidation (C- terminus). The
false discovery rate (FDR) threshold was set to 1% using a decoy database. Only high
and medium confidence protein matches were considered for downstream analysis.

Table 3- Search database file descriptions.
Sequence File

Description

# Sequences

1. Transcriptome A

Assembly of RNA-seq data from specimen 1

83,051

2. Transcriptome B

Assembly of RNA-seq data from specimen 14

84,410

3. Translated– getorf

Files 1 and 2 translated with getorf

231,175

4. Translated– transeq

Files 1 and 2 translated with transeq

1,004,766

5. ToxProt BLAST hits

Files 3 and 4 blasted against ToxProt database

1,652

6. C. purpurascens

C. purpurascens conopeptides including UniProt

40

Database

entries (taxid: 41690) and de novo sequences
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Figure 6- Workflow of the database search strategy.

2.6

Hierarchal cluster analysis and Principal Component Analysis
Total intensities for each conopeptide were normalized to the highest intensity within

each sample. Total intensities were normalized in this analysis to account for differences
in protein concentration between venom samples. Hierarchal clustering and Principal
Component Analysis were performed using ClustVis online software (v. 2018-12-20) [38].
Normalized intensities were log-transformed (ln(x + 1)) prior to hierarchal cluster analysis.
Hierarchal clustering was employed on both x- and y- axes using Pearson correlation
distance with average linkage.
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2.7

Alpha-conotoxin testing on nAChR subtypes

2.7.1 Alpha-conotoxin identification, selection, and synthesis
To identify putative α-conotoxin sequences, a conserved gene signal sequence was
obtained from Conoserver.org and used as a search query against the 17 transcriptomes
(BLASTp, e=10). Mature peptide sequences were predicted using SignalP software and
the predicted sequences were aligned using Geneious Prime (Biomatters, Aukland NZ).
From the alignment, we were able to assess inter-cysteine loop sizes and homology to
other functionally characterized α-conotoxins. Three peptides (α-PID, α-NuxIA, α-CedIA)
were chosen for functional assays on nAChRs and were synthesized by solid-state
synthesis through a third-party company to yield milligram quantities (GenScript,
Piscataway, NJ). The following post-translational modifications were incorporated:
disulfide bonds between C1-C3 and C2-C4 and amidation of the C-terminal. Once
received, peptide purity was confirmed by RP-HPLC separation on a C18 column. α-PIA
is commercially available and was purchased for functional screening (Alamone Labs,
Jerusalem, Isreal).
2.7.2 Oocyte harvesting and injection
Nicotinic receptor subtypes were heterologously expressed in Xenopus laevis oocytes.
Frogs were maintained in the Animal Care Service facility of the University of Florida, and
all protocols were approved by the University of Florida Institutional Animal Care and Use
Committee. First, oocytes were surgically removed from female frogs. The oocytes were
then injected with cRNA for the nAChR subunits required for the expression of one of
seven different receptor subtypes (Table 4). After injection, the oocytes were stored in
Barth’s solution (88 mM NaCl, 1 mM KCl, 2.38 mM NaHCO3, 0.82 mM MgSO4, 15 mM
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HEPES, and 12 mg/l tetracycline, pH 7.6) at 16 °C until electrophysiological experiments
were performed.

Table 4- NAChR subtypes with associated subunit RNA and ACh controls used
for voltage-clamp experiments.
nAChR
subtype
α3β4
α4α5β2
α4β2
α4β2
α4α6β2β3
α1β1εδ

α7

Subunit
RNA
hα3
hβ4
hβ2-6-α4
hα5
hβ2-6-α4
hα4
hβ2-6-α4
hβ2
hβ3α4β2α6β2*
mα1
mβ1
mε
mδ
hα7
hRIC3

ACh Control
(μM)
100
10
100
10
30
30

60

2.7.3 Two-electrode voltage-clamp recordings
Two-electrode voltage-clamp experiments were performed on an OpusXpress 6000A
using pClamp software (Molecular Devices, San Jose, CA). Oocyte membrane potential
was clamped at -60 mV and bath-perfused with Ringer’s solution (115 mM NaCl, 2.5 mM
KCl, 1.8 mM CaCl2, 10 mM HEPES, and 1 μM atropine, pH 7.2). Membrane current (μA)
was recorded throughout the following experimental protocol: pre-control (ACh), treatment
application (α-CNTX), co-application (ACh + α-CNTX), and post-control (ACh). ACh
controls were administered before and after α-conotoxin treatments to establish the oocyte
baseline response to ACh and the oocyte viability and receptor desensitization after
treatment. The ACh control concentration for each receptor subtype is reported in Table
4.
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2.7.4 Data analysis and IC50 calculation
Each experiment will have a sample size of 4-8 oocytes. Individual oocyte recordings
were eliminated from analysis if they were 1) unresponsive to the ACh pre-control 2) lost
their ‘clamp’ or holding potential (60mV) during the experiment or 3) had significant
desensitization to the post-control. Analysis of recordings was performed with Clampfit
software (Molecular Devices, San Jose, CA). Treatment response was measured as peak
current amplitude (μA). For each oocyte, the values for treatment response were
normalized to the ACh controls to account for differences in receptor expression levels
and ACh responsiveness between oocytes. T-tests were performed (n ≥ 3) for each
treatment on each nAChR subtype to test the hypothesis that the response of ACh controls
will be different from α-conotoxin + ACh treatments (p≤0.05). IC50 values were calculated
using an inhibitory dose-response curve nonlinear regression model with the following
equation: Y=Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)). When comparing αPIA and α-PID dose-response curves the hill slope was constrained to -1 with the
assumption that their binding mechanisms to the nAChR are similar.
2.7.5 Homology modeling of the human α7 nAChR
The structure of the α-PIA and α-PID bound to the human α7 nAChR (hα7) was
modeled based on the co-crystal structure of Aplysia californica AChBP bound to
conotoxin LvIA (PBD: 5XGL). First, the sequence of the extracellular domain of hα7 was
obtained from Uniprot (ID: P36544). An alignment file was created by aligning the hα7 and
α-PIA/α-PID sequence to the AChBP and LvIA sequence using the Clustal Omega
alignment algorithm within Geneious Prime (Biomatters, Aukland, NZ). Homology
modeling was performed using MODELLER (version 9.24) (University of California San
Fransisco)[79]. The resulting PDB files were visualized using UCSF ChimeraX software
[80] and analyzed for molecular energy and residue contact distances using Molecular
Operating Environment (MOE) (Chemical Computing Group, Montreal, Canada).
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CHAPTER 3:
PROTEOGENOMIC ASSESSMENT OF INTRASPECIFIC VENOM VARIABILITY IN
CONUS PURPURASCENS
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3.1

Introduction
Venomous animals comprise over 200,000 species across several taxa and display a

variety of mechanisms for venom production, delivery, and use [81]. For most animals,
venom is proteinaceous; however, different taxonomic groups independently evolved to
produce highly adapted venom as a solution to environmental pressures, a clear example
of convergent evolution. Most venoms are complex mixtures of peptides, proteins, and
small molecules that might act in concert to immobilize prey or deter predators. The
specific molecular content of these composites varies from phyla, class, order, family, and
genus. There can be also significant venom variability within the same species [82-90]. In
some cases, venom varies within the individual specimens [83, 91-95], as some animals
can switch their venom from predatory to defensive concoctions. Intraspecific venom
plasticity expands the molecular adaptations of venomous animals and in doing so
augments the remarkable repository of compounds with numerous applications that
include the development of pharmaceuticals, such as Captopril from the Brazilian pit viper
venom, Exenatide from the Gila monster, and Ziconotide/PrialtTM from cone snail venom
[3].
The venom found in marine predatory snails belonging to the genus Conus (cone
snails) has been intensely studied in terms of content and pharmacological properties.
Most notable are the conotoxins, a diverse group of disulfide-constrained (two or more
disulfide bonds) peptides that target ion channels, ligand-gated receptors, and
transporters with high affinity and selectivity [96, 97]. Conus venom can also contain linear
(no disulfides) and one-disulfide bond peptides [98], which along with conotoxins define
the conopeptides, the full small peptidic complement of the venom of cone snails.
Conopeptide diversity occurs at both the sequence and post-translational modification
(PTM) level, resulting in thousands of conopeptides that range in size, chemistry,
structure, and activity. Conopeptides/conotoxins are classified according to gene
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superfamilies based on conserved signal sequences, and each superfamily can encode
hundreds of mature conopeptide sequences [99-101]. Mature conotoxins have displayed
a plethora of cysteine frameworks and disulfide-bonding patterns, which in turn affects
activity. Conopeptide complexity also results from a high rate of PTMs [22, 102, 103]. The
same base peptide can have many differentially modified forms [104, 105], or ‘toxiforms’.
Conopeptide hyper-modification can be viewed as an evolutionary expansion of venom
genes used to engineer highly effective and potent toxins.
The molecular diversity of cone snail venom is extraordinary as its expression is
species-specific with little overlap of components among the more than 800 extant species
[106]. This complexity is compounded by intraspecific and intraspecimen venom variations
due to predatory or defensive venom profiles [90, 91, 93]. This complexity provides a rich
source of bioactive peptides [107, 108], but it also presents a challenge for venom
characterization. Intraspecies studies have relied heavily upon comparisons of venom
chromatography and mass-matching to known venom components, rather than global
MS/MS spectral matching, to identify venom components. A limitation of this approach is
that a single base conopeptide sequence can have many toxiforms with different masses.
This makes it difficult and rather uninformative to assess intraspecific venom variation
through molecular mass lists alone, and in doing so, it can lead to overestimates of the
extend of venom variability. Next-generation sequencing technology for RNAseq and
advances in high-resolution LC-MS/MS have mitigated the challenges associated with the
analysis of complex venoms and have allowed assessment of the venom
peptidome/proteome through ‘venomic’ approaches [109, 110].
A comprehensive analysis of the venom composition is crucial to assess venom
plasticity and to determine synergistic mechanisms of envenomation used to immobilize
prey or deter predators. Here, we present a large-scale intraspecific venom analysis of
Conus purpurascens, the only fish-hunting species of the tropical Eastern Pacific region.
25

Earlier groundwork revealed that C. purpurascens had two distinct venom ‘cabals’, or
groups of conopeptides acting synergistically to paralyze their prey [89, 111, 112]. The
cabals act as either 1) a neuromuscular block (motor cabal), targeting nicotinic
acetylcholine receptors (nAChRs, α- and ψ-conotoxins) and skeletal muscle sodium
channels (μ- conotoxins) or 2) an excitotoxic neuronal block (lightning-strike cabal),
targeting neuronal sodium (δ-conotoxins) and potassium channels (κ-conotoxins).
Previous works, however, were based on mass lists obtained from the venom of a limited
number of specimens [83, 89].
We present a comprehensive venom analysis by utilizing high-resolution LC-MS/MSbased peptide identification to analyze and compare injected venom from 27 individual
specimens of C. purpurascens. In doing so, we sought to maximize the identifications of
conopeptides and their toxiforms. We also assessed the biochemical diversity of the
venom arsenal by comparing conopeptide expression patterns to gain a more refined view
of synergistic relationships among the venom components.
3.2

Results

3.2.1 Conopeptide identification
Milked venom samples from 27 specimens of C. purpurascens were analyzed by LCMS/MS (Methods Section 2.4) and resulting MS/MS RAW files were searched against a
FASTA database that consisted of conopeptide sequences either acquired from RNA-seq
data or deposited in UniProt (www.uniprot.org) (Methods section 2.5). The venom analysis
yielded 543 unique conopeptide identifications, which included 33 base (or nascent)
conopeptides and their associated toxiforms (modified versions). Of these 33 base
conopeptides, 21 sequences were identified here for the first time (Table 5). Detailed
descriptions of each new conopeptide are provided in Appendix C. Twenty-six of the
conopeptides were identified through the transcriptome search database (RNA-seqassembled transcripts). However, seven conopeptides were identified in the venom but
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were not found in either of the transcriptomes. Four of these peptides were identified from
C. purpurascens UniProt entries (α-PIA, α-PIB, κ-PIVF, PVIF), and three conopeptides
were sequenced de novo and manually added to our in-house search database
(Contryphan-P4, PIF, and PIG). For the conopeptides that were identified from RNA-seq
data, full or partial transcripts were used to assign superfamilies through their
corresponding signal sequence (Table 6).
The number of base conopeptide IDs per sample of injected venom ranged from 5-17
(mean= 10.6 ± 2.6) (Figure 7). The most prevalent conopeptide in this population of snails
was Ile-contryphan-P, identified in 25 of the 27 venom samples. This was followed closely
by conopeptides κ-PVIIA, PVIIIA, ψ-PIIIE, α-PIVA, and PVIB, all identified in more than
75% (n > 20) of the venom samples (Figure 8).
Differentially modified toxiforms were identified for 27 of the 33 base conopeptides
(Table 5). Toxiforms were only considered if the peptide maintained a complete cysteine
framework. The PTMs identified through MS/MS analysis included amidated C-terminal,
hydroxyproline,

oxidized

methionine,

deamidated

asparagine/glutamine,

carboxyglutamate, brominated tryptophan, N-terminal pyroglutamate, and truncations
from both terminals (Appendix A). The most abundant PTMs were C-terminal amidation
and hydroxyproline, which occurred on 75% of the base conopeptides identified. The
same modification(s) occurred on different residues of the same peptide, generating
unique toxiforms with the same molecular weight. This is the case of hydroxyproline, which
occurred on up to three residues simultaneously on four peptides: α-PIVA, ψ-PIIIE, PVIE,
and PVIG. Differential hydroxylation patterns are seen for these conopeptides (Appendix
A). The greatest PTM variability was observed on A-superfamily conotoxins α-PIVA (98
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toxiforms) and κ-PIVE (69 toxiforms), and new O1-superfamily conopeptide PVIB (67
toxiforms) (Table 5).
Table 5 Conopeptides identified from the injected venom of Conus
purpurascens. Conopeptides reported for the first time here are in bold. Sequence
alignment was performed manually for each cysteine framework. *Conopeptides
identified with the PEAKS de novo software. **These base conopeptides were
previously described from cDNA libraries as P2B-D [1]; since these designations do
not conform with current nomenclature they were renamed accordingly. The number
of toxiforms only includes peptides identified with the full cysteine framework. ND =
not determined because there were no spectral matches associated with the
complete base peptide.
Superfamily
A
A
A
A
A
A
A
A
A
A
A
B2
M
M
ND
M
M
M
M
O1
O1
O1
O1
O1
ND
O1
O1
O2
O3
S
T
T
Con-ikot-ikot

Conopeptide
α-PIA
α-PIB
α-PIC
PID
PIE
PIF*
PIG*
αA-PIVA
κ-PIVE
κ-PIVF
PIVH
Linear-P
Ile-Contryphan-P
Contryphan-P3
Contryphan-P4*
ψ-PIIIE
PIIIG
PIIIH
PIIII
δ-PVIA
PVIB
PVIC
PVID**
PVIE
PVIF**
PVIG**
κ-PVIIA
Contryphan-P
PIIA
PVIIIA
PVA
PVB
p21b

Sequence
RDPCCSNPVCTVHNPQIC
QSPGCCWNPAC-VKNR—C
TSGCCKHPAC-GKNR—C
DPCCSNPACNVNNPQICG
NAAAKAFDLTAPTAGEGCCFNPACAVNNPNIC
QEPGCCRNPAC-VKHR—C
PCCSNPVCTVHGGPQLC
GCCGSYPNAACHPCSCKDRPSYCGQ
DCCGVKLEM-CHPCLCDNSCKNYGK
DCCGVKLEM-CHPCLCDNSCKKSGK
DCCGVVMEE-CHKCLCNQTCKKK
QPSAENEEGKFRFFDKQ
GCVIWPWC
CAIWTKC
CVYWRKC
HPPCCLYGKCRRYPGCSSASCCQR
QWGCCPVNACRSCHCC
KCCPLTACKLGSGCKCCE
CCQA-YCSRYHCLPCC
EACYAPGTFCGIKPGLCCSEFCLPGVCFG
QCTPYGGSCGVD-STCCGRCNVPRNKCE
EACYAPGTFCGIKPGLCCSALCLPAVCID
PCKKSGRKCFPHQKDCCGRACIITICP
VGEFRGCAHINQACNPP-QCCRGYTCQSSYIPSCQL
ATSNRPCKKTGRKCFPHQKDCCGRACIITICP
GATSNRPCKIPGRKCFPHQKDCCGRACIITICP
CRIPNQKCFQHLDDCCSRKCNRFNKCV
GCPWDPWC
CCCIRSDGPKCSRKCLSSFFC
GCSGSPCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE
GCCPKQMRCCTL
DCCPEKMWCCPL
FELLPSQDRSCCIRKTLECLENYPGQESQRAHYCQQDATTN
CPDTYDFGCCPGYATCMSINAQNNVRPAHDTCINRLCFDPG
F
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Toxiforms
18
6
1
11
2
13
2
98
69
32
45
6
7
3
1
27
2
7
1
3
67
ND
3
16
3
16
18
1
2
33
2
11
ND

Table 6- Protein sequences of identified conopeptides. Sequences were translated from RNA-seq transcripts from venom duct
transcriptomes A (unshaded) and B (shaded). Mature peptides, as determined by MS/MS, are in bold.
Superfamily

Conopeptide

Transcript

A

PIC
PID
PIVA

MGMRMMFIVFLLVVLATTVGSFTLDRVLGLASEGRNAEAIDNALDQRDPKRRTSGCCKHPACGKNRC
MGMRMMFIVFLLVVLATTVVSFTLDRASDGRDAAANDKASDLIALTARRDPCCSNPACNVNNPQICG
MGMRMMFIVFLLVVLATTVVSFTSDRASDDRNTNDKASRLLSHVVRGCCGSYPNAACHPCSCKDRPSYCGQGR
MGMRMMFIVFLLVVLATTVGSFTSDRASDDRNTNDKASRLLSHVVRGCCGSYPNAACHPCSCKDRPSYCGQGR
MGMRMMFIVFLLVALATTVGSFTSDRASDGRNAAVNDKASHLIDNVIRDCCGVKLEMCHPCLCDNSCKNYGKGKKEYGK
VVLATTVVSFTSDRASDGRNAAVNDKASPLIAKVIRDCCGVVMEECHKCLCNQTCKKKGKKELWEMMTATDKRNT
MLRLIIAAVLASACLAFPERRDGVPAEQANLQGFDPAAQAMPAMAGMQQMPGMAGGQFLPFNPNFGMAYKRDMDESLEKRKQHSQFNADNESPFEAGDNLGDFM
NFMKGNGNNVPFANMDSDATDLGNFQPSAENEEGKFRFFDKQQ
MLRLIIAAVLASACLAFPERRDGVPAEQANLQGFDPAAQAMPAMAGMQQMPGMAGGQFLPFNPNFGMAYKRDMDEILEKRKQHSQFNADNESPFEAGDNLGDFM
NFMKGNGNNVPFANMDSDATDLGNFQPSAENEEGKFRFFDKQQ
MLKMGVLLFTFLVLFPLATLQLDADQPVERYVEKKQDLNPDERTKTLHALRPPSVDKRATSLGCVIWPWC
MLKMGVLLFIFLVLLPLATLQLDADQPVERYAENKQDLKPDERREIILPALGPPSVDKRATSLACAIWTKC
MMSKLGALLTICLLLFPITALLMDGDQPADRPAERMEDDISSEVHRLLERRHPPCCLYGKCRRYPGCSSASCCQRG
MMSKLGALLTICLLLFPITALLMDGDQPADRPAERMEDDISSEVHRLLERRHPPCCLYGKCRRYPGCSSASCCQRG
LITLQLDADQPVERYAEDKQDLNPNERMGFILPALRQWGCCPVNACRSCHCCGRSTSVALCWADSTATAVVDHVYYRAHVSCLRMTN
MLKMGVLLFTFLVLFPLATLQLDADQPVERYAENKQDLKPDERREIILPALGQRKCCPLTACKLGSGCKCCE
MMFKLGVLLTICLLLVPLTAIPLDGDQPVDQPAERMEDGKSTPNHPWFDPVKRCCQAYCSRYHCLPCC
MKLTCVMIVAVLFLTAWTFVTADDSKNGLENHFWKARDEMKNREASKLDKKEACYAPGTFCGIKPGLCCSEFCLPGVCFGG
MKLTCVMIVAVLFLTAWTFVTADDSKNGLENHFWKARDEMKNREASKLDKKEACYAPGTFCGIKPGLCCSEFCLPGVCFGG
MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKLSMLTRQCTPYGGSCGVDSTCCGRCNVPRNKCE
MKLTCVMIVAVLFLTAWTFVTADDSKNGLENHFWKARDEMKNREASKLDKKEACYAPGTFCGIKPGLCCSALCLPAVCIDG
MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKRARSNRPCKKSGRKCFPHQKDCCGRACIITICP
MKLTCVLIIAVLFLTACQLITAGYSRDKQVYRAVRLGDKMLRVGEFRGCAHINQACNPPQCCRGYTCQSSYIPSCQL
MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKGATSNRPCKIPGRKCFPHQKDCCGRACIITICP
MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKLSLSTRCRIPNQKCFQHLDDCCSRKCNRFNKCV
MKLTCVVIVAVLFLTACQLITADDSRRTQKHRALRSTTKLSLSTRCRIPNQKCFQHLDDCCSRKCNRFNKCV
MGKLTILLLVAAVLLSTQVMVQGDGDQPAYRNAAPRDDNPGGAIGKFMNVLRRSGCPWDPWCG
MSRFGIMVLTFLLLVSMATSHRYARGKQATRRNAINIRRRSTPKTEACEEVCELEEKHCCCIRSDGPKCSRKCLSSFFC
MMSKMGAMFVLLLLFTLASSQQEGDVQARKTRLTRDFYRTLPVSTRGCSGSPCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE
MMSKMGAMFVLLLLFTLASSQQEGDVQARKTRLTRDFYRTLPVSTRGCSGSPCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE
MRCLPVFVILLLLIASAPSVDAHPKTKDDMPLASFHDNAKGTLQRLWKKRGCCPKQMRCCTLG
MHCLPVFVILLLLIPSAPCVDAHPKTKDDMPLASFHDNAKRTLQRFWKKRDCCPEKMWCCPLG
MRCLPVFVILLLLIASAPSVDAHPKTKDDMPLASFHDNAKRTLQRFWKKRDCCPEKMWCCPLG
MNMSMTLSMFVMVVVAATVTGFELLPSQDRSCCIRKTLECLENYPGQESQRAHYCQQDATTNCPDTYDFGCCPGYATCMSINAQNNVRPAHDTCINRLCFDPGF

B2

M

O1

PIVE
PIVH
B2 linear

Ile-Contryphan-P
Contryphan P3
PIIIE
PIIIG
PIIIH
PIIII
PVIA
PVIB
PVIC
PVID (P2b)
PVIE
PVIG
PVIIA

O2
O3
S

Contryphan-P
PIIA
PVIIIA

T

PVA
PVB

Con-ikot-ikot

P21b
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Figure 7- Conopeptide IDs for 27 C. purpurascens injected venom samples.

Figure 8- Conopeptide frequency in injected venom of C. purpurascens. N= 27
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3.2.2 Intraspecific venom comparison
Hierarchal cluster analysis was employed to compare the venom profiles based on the
total ion intensity of each base peptide (Methods Section 2.6). Total ion chromatograms
(TIC) of injected venom (Appendix B) and conopeptide profiles varied among the 27
samples. Two groups were distinguished from cluster analysis of the 33 base
conopeptides, specimens 1-7, and 8-27 (Figure 9). Clustering along the y-axis
distinguished two groups of conopeptides that correlate to different venom compositions.
The first cluster (snails 1-7) is mainly comprised of δ- and κ-conotoxins that target the
sodium and potassium channels, respectively. These conotoxins make up the ‘lightning
strike’ cabal that rapidly immobilizes prey by acting on ion channels. The second cluster
(snails 8-27) contains ψ- and α- conotoxins that both act on nAChRs and make up the
‘motor cabal’. Principal Component Analysis supported this dual expression pattern in the
venom and clustered samples into two distinct groups of specimens 1-6 and specimens
8-26, with specimens 7 and 27 as outliers (Figure 10A). An overlay of chromatograms
from specimen 5 from cluster 1 (blue) with specimen 14 from cluster 2 (red) emphasizes
the distinction in venom profile components between the two clusters (Figure 10B).
The conopeptide identifications were made from venom gland transcriptome
databases of two C. purpurascens specimens (transcriptomes A and B). These specimens
correspond to specimen venom samples 1 (snail sacrificed for transcriptome A) and 14
(snail sacrificed for transcriptome B). To assess the coverage of the milked venom sample
by the corresponding transcriptome, we compared conopeptide expression between these
two specimens (Table 7). Our comparison examines the expression of each peptide
between the two specimens at both transcriptomic (TPM) and proteomic (relative intensity)
levels. Conopeptides expressed in the venom gland but not identified in the injected
venom sample are shown in grey. Conopeptides identified in injected venom sample, but
not expressed in venom gland transcriptome are shown in blue. Overall, we see a
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differential expression pattern between the two specimens and between transcriptomic
and proteomic expression within the same specimen.

Figure 9- Conopeptide profiles from 27 C. purpurascens specimens. Ion intensities
were normalized to the highest value for each specimen and ln(x + 1)-transformed.
Clusters were determined by hierarchal cluster analysis using correlation distance and
average linkage.
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Figure 10- C. purpurascens expresses two distinct venom profiles. A) PCA analysis of normalized ion intensity for all
conopeptide IDs (n= 27). B) Total Ion Chromatogram (TIC) overlay of Specimen 14 from cluster 1 (blue) and specimen 1
from cluster 2 (red).
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Table 7- Comparison of transcriptome expression and MS identification from
two specimens of C. purpurascens (Specimen 1-Transcriptome A, Specimen 14Transcriptome B). Differential patterns of expression are shown by shading.
Conopeptides expressed in the venom duct but not identified in the injected venom
sample are shown in grey. Conopeptides identified in injected venom sample, but not
expressed in venom duct transcriptome
are shown in blue.
Specimen 1
Specimen 14
Superfamily

Conopeptide

A
A
A
A
A
A
A
A
A
A
A
B2
M
M
?
M
M
M
M
O1
O1
O1
O1
O1
?
O1
O1
O2
O3
S
T
T
Con-ikotikot

α-PIA
α-PIB
α-PIC
PID
PIE
PIF
PIG
α-PIVA
κ-PIVE
κ-PIVF
PIVH
Linear-P
Ile-Contryphan-P
Contryphan-P3
Contryphan-P4
ψ-PIIIE
PIIIG
PIIIH
PIIII
δ-PVIA
PVIB
PVIC
PVID
PVIE
PVIF
PVIG
κ-PVIIA
Contryphan-P
PIIA
PVIIIA
PVA
PVB
P21b

Transcriptome A
(TPM)
0.00
0.00
6657.49
139.43
25.81
0.00
0.00
8002.60
0.00
0.00
3962.08
7081.46
1985.81
0.00
0.00
1926.10
6.84
0.00
0.00
2642.86
0.00
632.78
363.92
0.00
0.00
0.00
934.23
57382.30
22.33
4082.19
340.10
73.58

MS
Relative
Intensity
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
989.76
1000.00
0.00
1.23
0.00
1.29
0.00
0.00
0.00
0.02
13.74
58.13
14.82
3.02
0.00
0.00
0.00
935.37
0.00
0.00
0.00
0.00
0.00

Transcriptome B
(TPM)
0.00
0.00
1214.88
0.00
50.15
0.00
0.00
7115.58
1043.68
0.00
0.00
2802.38
0.00
512.22
0.00
770.99
0.00
2988.25
8.32
3651.60
257.39
0.00
0.00
152.04
0.00
569.10
1387.09
4647.95
0.00
1193.34
0.00
403.84

MS
Relative
Intensity
0.00
0.00
0.00
67.16
0.00
0.00
0.00
1000.00
0.22
0.00
0.00
0.00
0.38
0.87
0.00
186.94
0.00
97.70
0.00
0.00
0.75
0.00
0.00
0.01
0.00
0.00
21.09
0.00
0.00
74.22
2.68
0.83

0.00

0.00

71.93

4.46
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3.2.3 Novel S-superfamily conotoxin- PVIIIA
PVIIIA is one of the 21 newly identified conopeptides and is the first member of the Ssuperfamily found in injected venom. The peptide has five disulfide bonds and exhibits
cystine framework VIII (C-C-C-CXaaC-CXaaC-CXaaCXaaC). It was expressed in high
frequency and abundance within this C. purpurascens population. It was identified in 23
of the 27 venom samples (Figure 8). When venom profiles were compared, PVIIIA
expression clustered closely with α-PIVA and ψ-PIIIE, which both target nicotinic receptors
as part of the motor cabal (Figure 9). Alignment with functionally characterized Ssuperfamily conotoxins, known to target serotonin (σ-GVIIIA) and nicotinic (α-GVIIIB, αRVIIIA) receptors, exhibits very little sequence homology aside from the conserved
cysteine framework (Figure 11). PVIIIA is 41 residues in length and has 5 sites of
modification, as determined by MS/MS spectral matching. We mapped all identified PTMs
for the 33 toxiforms of PVIIIA (Appendix A). The following sites of modification were
determined: oxidated Pro(6), carboxylated Glu(16), deamidated Asn(10, 24), and
truncations on both N- and C- terminals. These modifications occur in most possible
combinations, significantly expanding the molecular diversity of the PVIIIA base peptide.
We also compared toxiform expression among the 27 specimen samples (Figure 12). The
heatmap shows two clusters of peptides, which correlate to high abundance (top cluster)
and lower abundance (bottom cluster). The six toxiforms in the top cluster exhibit the
highest expression within the samples, as shown by color, and also within the population

Figure 11- Alignment of PVIIIA with characterized S-superfamily conotoxins
σ-GVIIIA, α-RVIIIA and α-GVIIIB. Cysteines are highlighted in yellow to
emphasize a conserved cysteine framework.
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Figure 12- PVIIIA toxiform expression from 27 C. purpurascens specimens. Total
ion intensities were calculated for each toxiform. Ion intensities were normalized to the
highest value for each specimen and ln(x + 1)-transformed. Rows and columns are
clustered using correlation distance and average linkage.

3.3

Discussion
Proteogenomic approaches, including functional genomics (transcriptomics), are

ideally suited to study venom. The proteinaceous nature of venom allows a
comprehensive assessment of the venom composition (venome) and the study of venom
dynamics (venomics). Here, we have applied venomics to study the intraspecific variability
of the injected predatory venom used by C. purpurascens, a fish-hunting cone snail that
has been studied intensively for the past 25 years [113, 114]. Studies on cone snail venom
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are quite significant, as the venom is a valuable source of bioactive peptides that can be
used as neuronal probes and developed as novel therapeutic agents. Several
conopeptides have reached clinical trials, including the approval of PrialtTM, among the
most powerful painkillers known [18].
Analysis of the intrinsic complexity of cone snail venom has been significantly
advanced with the advent of NGS transcriptomic data that provides thousands of novel
putative conopeptide sequences-- a trend that will continue to expand. It is critical to probe
venom using proteomic approaches, as transcriptomic data on its own can only provide
putative sequences. Large scale top-down proteomics/peptidomics is the best way to
assess de facto PTMs and cleavage sites to generate mature conopeptides. We sought
to maximize venom coverage through conopeptide identifications; however, practical
aspects of these workflows, such as the number of available transcriptomes, size of the
conopeptides suitable for “top-down”/enzyme-free methods, and unforeseen PTMs, may
have an effect on the final coverage of components obtained. While recognizing these
limitations for complete venom coverage, we were able to increase component
identification by including sequences discovered through de novo methods and
sequences previously reported for C. purpurascens to our search database. Regardless
of the total coverage obtained, our results reveal a clear picture of the venom profiles and
envenomation strategies employed by C. purpurascens.
We show through a functional proteogenomic comparison between specimens 1 and
14 that transcriptomic data from the venom gland does not provide complete coverage of
the venom components. We identified conopeptides in the injected venom that were not
represented at the transcript level, demonstrating the lack of homogeneity between the
venom gland transcriptome and the injected venom. Of the 17 conopeptides reported in
UniProt for C. purpurascens, 7 were not found in either venom gland transcriptome (αPIA, α-PIB, μ-PIIIA, ψ-PIIIF, κ-PIVF, p21a, conantokin-P, and Leu-contryphan-P). By
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combining transcriptomes from two specimens into a search database, we were able to
increase our total proteome coverage of the venom. However, these results emphasize
that a transcriptome is a snapshot of gene expression at the precise moment the animal
was sacrificed for mRNA extraction and cannot be used alone to fully describe the
dynamics of venom expression. Other limitations include missing toxin transcripts during
the transcriptome assembly process, as de novo assemblers can face difficulties when
attempting to process large numbers of closely related transcript isoforms [115].
We aimed to achieve high-confidence peptide identifications to help describe the
molecular mechanisms of predations utilized by this population of C. purpurascens. Our
venomics approaches led to the identification of 543 conopeptides, which are the result of
33 base sequences and their corresponding toxiforms, significantly expanding the current
inventory of C. purpurascens conopeptides. As expected, these are only a fraction of the
putative conopeptide base sequences predicted by transcriptomic expression or by the
number of unique masses deconvoluted at the MS1 level [89]. We were able to ascertain
numerous toxiforms from the 33 identified base conopeptide sequences. Cone snails have
the remarkable ability to engineer their venom peptides through hyper-modification, a
molecular adaptation to hunting strategy [22, 103, 104]. These PTMs may have important
implications for the development and molecular engineering of novel peptide-based
therapeutics [116-118]. Using spectral matching we were able to detect sites of differential
hydroxylation and carboxylation, which could not be deciphered through mass matching
alone.
Our results emphasize the importance of identifying venom components from the
injected venom, the actual brew delivered into prey. This is in striking contrast to
intraspecific studies that utilized dissected venom [85, 119], which neglect venom
processing and delivery at several levels. This is the first study using high-resolution mass
spectrometry, transcriptomic data and de novo approaches on the injected venom of a
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large group of individuals of the same species for the global identification of components,
assessment of venom dynamics, and evaluation of synergistic interactions between
conopeptides and their potential pharmacology.
The conopeptide composition of the predatory injected venom arsenal of C.
purpurascens consists of cysteine-constrained peptides that range from 1 disulfide bond
(contryphans) to 5 disulfide bonds (PVIIIA and p21b). The outlier is the linear peptide
(Linear-P) belonging to the B2-superfamily. The molecular masses ranged from 938 Da
(Contryphan-P3) to 4960 Da (PVIIIA), indicating a wide spread of molecular features of
these venom components. These venomes are covered by conotoxin frameworks I-VIII,
X, and 21. Except for frameworks II, VIII, and 21, 3D structural information exists to help
assign disulfide bonding and folding patterns [120-123] to these newly discovered C.
purpurascens conotoxins. This is particularly true for the well-studied α-conotoxins
(framework I) and κ-, δ-conotoxins (frameworks VI, VII). Structural assignments of the
more complex frameworks, such as those found in PVIIIA and p21b (5 disulfide bonds),
remain a challenge. While the structural and even functional features of novel base
sequences can be predicted by homologies, such as PID, PIE, PIF (which are homologs
of other well-characterized α-conotoxins), others such as PIIA, PIIIG-I, PVIE, and PVIIIA
have no significant homology to functionally characterized conotoxins; and therefore their
activity and role in the envenomation strategy will require further investigation.
Hierarchical cluster analysis of the venom profiles of 27 specimens enabled us to
ascertain strong linkages and possible synergisms between specific conopeptides through
co-expression patterns. We found two distinct clustering patterns indicating that two
different venom cabal combinations can be employed by C. purpurascens as a hunting
strategy. Cluster 1 contains classical members of the lightning strike cabal, affecting
neuronal transmission by disrupting the propagation of action potentials (δ-PVIA, κ-PVIIA,
κ-PIVE), but not apparent members of the motor cabal, comprising paralytic toxins acting
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primarily on nicotinic muscular targets (α or αA conotoxins). These findings provide a
significant revision to the original venom cabal configurations for C. purpurascens. The
original cabal concept was introduced by the synergy of conotoxins -PVIIA and -PVIA
(the lockjaw peptide) found in the pooled venom from several individuals of C.
purpurascens collected in the Gulf of California [111, 113]. However, when using pooled
venom, the lightning strike cabal would be complemented with members of the motor
cabal that includes several inhibitors of nAChRs such as a A (PIVE, PIVF, PIVG) and
ψM (PIII-I) conotoxins, which is not the case for individuals within cluster 1 (non-pooled
samples). Since conotoxins PIVE, -PVIIA, -PVIA, and their respective toxiforms, and
novel conotoxins, PIVH, PVIB, PVIC, PVID (and toxiforms), are part of cluster 1, the latter
appear to complement the lighting strike cabal within those C. purpurascens individuals.
Cluster 2 contains several inhibitors of nAChRs such as -PIA-F, A-PIVA, and ψPIIIE conotoxins in addition to components of the lighting strike cabal, δ-PVIB and κ-PVIIA
(also present in cluster 1). This is an indication of the use of multiple cabals as the primary
arsenal of this population of C. purpurascens. The role of PVIIIA is intriguing, as it is highly
expressed in cluster 2, but given the abundance of nicotinic inhibitors already present
there, it would be unlikely that another more complex nicotinic inhibitor is necessary to
complete the motor cabal. Another curious finding within cluster 1 was the presence of
mini-M conotoxins PIIIG, PIIIH, and PIII-I. While these conotoxins are prevalent in worm
and mollusk-hunting Conus species [124, 125], they have not been found in the injected
venom of fish hunting species until now. The significance of this finding is under
investigation.
We use PVIIIA as an example to demonstrate toxiform variability among the 27 venom
samples. A heatmap of PVIIIA toxiforms shows two clusters of peptides (Fig. 6), high
abundance (top cluster) and lower abundance (bottom cluster). While the toxiform
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comparison does not provide insight into its role in the venom, it can help distinguish which
toxiforms are most abundant within the population and provide leads for downstream
bioactivity assays.
Populations of cone snails in different habitats and geographical locations can show
different venom phenotypes, as seen in C. purpurascens venom studies carried out on
animals from the Gulf of California [111], The Clipperton atoll [126], Ecuador [127],
Panama [83] and Costa Rica [90] showing profound differences in venom profiles. For
example, p21a, a conotoxin with the putative ability to modulate AMPA receptors, was
found in a C. purpurascens specimen from Ecuador [127], but not in the animals from
Costa Rica here studied. However, the homologous conotoxin p21b was found as part of
cluster 2, but not cluster 1. Given the differences in cabals between clusters 1 and 2, it is
likely that p21b participates in the lightning strike cabal within cluster 2 instead of PVIA,
which is absent in this cluster. Habitat is critical to these slow-moving creatures as they
must adapt to very localized areas. Part of this adaptation process will be venom
production to capture prey that is prevalent to these microhabitats. Accordingly, venom
profiles that we found might be a product of such an adaptation. This adaption appears to
be imprinted over their development in the wild, as upon captivity, the venom remains
invariant as these animals were fed and kept under identical conditions.
Despite extensive studies on C. purpurascens through decades, using HR-MS/MS
spectral matching, we have revealed a deeper coverage of the components of the injected
venom from 27 specimens of C. purpurascens. Furthermore, we have shown the dramatic
venom variations from specimen to specimen and the dynamic interaction of components
as revealed by two patterns of synergism. These findings further develop the cabal
concept in several ways. 1) The expanded reach of components due to the hypermodification to generate a plethora of toxiforms, 2) novel components belonging to distinct
cabals, and 3) the possibility of multiple cabals operating independently within the same
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geographical group of individuals. In addition to providing the strongest evidence of venom
cabals to date, these findings will allow us to predict molecular targets of uncharacterized
conopeptides based on global expression patterns. These analyses will tremendously aid
the convoluted process of developing conotoxins/conopeptides into valuable molecular
probes or therapeutics.
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CHAPTER 4:
INSULIN-LIKE PEPTIDE FROM THE INJECTED VENOM OF
CONUS PURPURASCENS
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4.1 Introduction
Insulin and insulin-like peptides (ILPs) belong to a superfamily of 6-9 kDa hormone
peptides that are involved in growth and metabolism. ILP gene sequences encode signal
peptides followed consecutively by B-chain, C-chain, and A-chain peptides. The protein is
proteolytically processed into its active form containing A-and B-chain peptides connected
by two disulfides [128]. Human insulin has provided critical information on the structure
and function of the insulin scaffold, including the key amino acid residues needed for
insulin dimerization and receptor binding [129-131]. These findings enabled the production
of human recombinant insulin therapy, Humulin [132], and its fast-acting analog, Humalog,
or insulin lispro [133]. The commercialization of insulin has significantly prolonged the
lifespan and improved the quality of life for hundreds of millions of diabetics worldwide
[134].
The insulin superfamily is a diverse group of hormone peptides that are found
throughout animal phylogenies, from unicellular organisms to the most complex
vertebrates [135]. In vertebrates, the superfamily includes insulin, insulin-like growth
factors (IGF-1 and IGF-2), and relaxin, which are involved in glucose metabolism, growth,
and pregnancy, respectively. Invertebrates have greatly expanded the function of the
insulin superfamily through a diversity of ILPs. Unlike their vertebrate counterparts,
invertebrate ILPs are the products of multi-gene families. This gene expansion is reflected
through tissue heterogeneity and the multi-faceted physiological role of ILPs within
invertebrate systems [136-139]. Examples of well-studied invertebrate ILPs include the
insect bombyxins [140], molluscan insulin-like peptides (MIPs) [141, 142], and Drosophila
insulin-like peptides (DILPs) [143]. Invertebrate ILPs are involved not only in carbohydrate
metabolism and growth, but also in reproduction, diapause, aging, and immunity [144].
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Gene diversification has led to the incorporation of endogenous peptide hormones into
animal venom as an evolutionary tactic to disrupt the normal endocrine function in the prey
[145, 146]. Because venom peptide hormones mimic endogenous hormones, they are
promising candidates for drug development. For example, the glucagon-like peptide,
exenatide, from the Gila monster saliva, mimics the exogenous hormone incretin that
helps increase insulin release after a meal and it was developed into ByettaTM, a drug used
for the management of Type II-diabetes [147].
The first record of an insulin-like peptide (ILPs) from animal venom came from Conus
geographus (Con-Ins G1), a fish-hunting cone snail species from the Indo-Pacific region
[148]. Cone snail venom is a complex mixture of peptides, proteins, and small molecules
that contains several classes of hormone-like peptides, such as conopressins
(oxytocin/vasopressin analogs) [149], conoCAPS (crustacean cardioactive peptide-like
peptides) [150], and RFamides [151]. Proteomic analysis of C. geographus venom
revealed a peptide resembling fish-like insulin that when synthesized and tested,
decreased blood glucose in feeder fish, causing rapid immobilization. Since then,
transcriptomic data from venom ducts have revealed a diversity of ILPs from across the
Conus genus. Some Conus species use ‘weaponized-insulin’ in their venom that more
closely resemble vertebrate insulin than MIPs [152]. These vertebrate-like insulins lack an
extra cysteine pair that is found in MIPs. Con-Ins G1 shows modest activity against the
human insulin receptor, despite low homology to human insulin [153]. Conoinsulins from
other fish-hunting species, C. tulipa and C. kinoshitai, also bind and activate the human
insulin receptor [154]. Conoinsulins also contain unique post-translational modifications
(i.e., carboxylated glutamic acid) that may enhance their ability to bind and activate the
insulin receptor, as suggested by increased receptor binding activity of Con-Ins G1 as
compared to the PTM-free peptide [153].
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The functionality of conoinsulins at the human insulin receptor has opened the door
for screening these venom ILPs as pharmacological agents. Recently, Con-Ins G1 has
been used as a scaffold for developing a minimized human insulin peptides (mini-Ins)
[155]. Mini-Ins is a truncated monomeric insulin peptide that binds and activates the insulin
receptor with comparable potency to human insulin. Using Con-Ins G1 as a model,
alternative binding mechanisms were determined that allowed for engineering minimized
yet fully functional human insulin peptides.
Here, we describe a new conoinsulin (Con-Ins P1) found in the injected venom of C.
purpurascens, a fish-hunting cone snail that inhabits the tropical Eastern Pacific region.
C. purpurascens venom is well-studied and is known to contain conotoxins targeting
sodium channels [113, 156], potassium channels [157], nicotinic acetylcholine receptors
[158-161], as well as enzymes such as hyaluronidases [162], ACE, ECE [163] and
conodipines [114]. Con-Ins P1 differs considerably in sequence and arrangement from
other conoinsulins as it has a not truncated B chain. It is the first discovery of a hormonelike peptide from C. purpurascens venom, and the first direct evidence of conoinsulins
being used in injected venom for prey capture.
4.2

Results

4.2.1 Phylogenetic analysis of ILP expression
Insulin superfamily proteins were compiled from the InterPro database (IPR036438).
The InterPro database contained a total of 5,000 entries for the insulin superfamily (258
reviewed), which included 942 unique taxa (123 reviewed). When considering reviewed
entries alone, 85% of them are from chordates, and ~50% of these are from mammals
(Figure 13). Invertebrate taxa include gastropods, insects, echinoderms (starfish), and
nematode species. Gastropod taxa comprise ~10% of the InterPro insulin superfamily
database; 65 entries from 31 Conus species and 2 entries from the venomous turrid sea
snail, Unedogemmula bisaya (Tax ID: 746885). The reviewed proteins include 28 entries
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from gastropods; 22 entries from cone snails and the remainder from model species
Aplysia californica (Tax ID: 6500) and Lymnaea stagnalis (Tax ID: 6523) (Appendix D).
Within the unreviewed Conus entries, 13 sequences exhibit the cysteine framework of
vertebrate-like insulins rather than MIPs (Figure 14). These vertebrate-like insulins come
from C. kinoshitai (2), C. geographus (6), C. tulipa (4), and C. lenavati (1). All the above
are fish-hunt ing species except for C. lenavati, which is a worm-hunter.

Figure 13- Phylogenetic tree of the insulin superfamily.
Entries are from Interpro database (IPR036438, reviewed).
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Figure 14- Conoinsulins that exhibit a vertebrate-like insulin cysteine framework Sequences
are from InterPro insulin superfamily database (IPR036438, unreviewed entries).
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Figure 15- Conoinsulin sequences expressed in C. purpurascens tissue.
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4.2.2 ILP expression in C. purpurascens tissues
Transcriptomes from six different C. purpurascens tissue types were analyzed for ILP
expression: venom duct, venom bulb, proboscis, eye, liver, and foot. In total, 4 transcripts
encoding ILPs were identified (Figure 15). The transcripts exhibit heterologous expression
among the different tissue types (Table 9). Con-Ins P1 is the most ubiquitously expressed
in all tissue types, aside from the liver or foot where no ILP expression was found. ConIns P1 has the highest expression in the venom duct (866 TPM) and the venom bulb (143
TPM). P1 expression is significantly lower in the eye (12 TPM) and proboscis (9 TPM).
Con-Ins P2 was also expressed in the venom duct (89 TPM); however, this protein was
not identified through MS/MS analysis of the milked venom. Con-Ins P3 was expressed in
low quantities (1-3 TPM) in the venom duct, bulb, and eye, and Con-Ins P4 was expressed
only in the eye (2 TPM).
Con-Ins P1 exhibits a cysteine framework more like vertebrate insulins than
molluscan-type insulins. When comparing the A and B chain peptides between the four
transcripts, Con-Ins P1 has one less cysteine residue in each, resulting in one less interpeptide bond. Con-Ins P1 shares a cysteine framework with other venom insulins from
fish-hunting cone snail species (Figure 14). Con-Ins P3 and P4 are homologous to other
MIPs, exhibiting an 8-cysteine framework. Interestingly, Con-Ins P2, also expressed in the
venom duct, exhibits a hybrid sequence. It has an identical A chain peptide to Con-Ins P1,
but its B chain is more like molluscan-type insulins Con-Ins P3 and P4.
Table 8- RNA expression of conoinsulins in C. purpurascens tissues.
RNA expression
(TPM)
Venom Duct
Venom Bulb
Eye
Proboscis
Liver
Foot

Con-Ins P1

Con-Ins P2

Con-Ins P3

Con-Ins P4

866.51
143.13
12.34
9.12
0
0

89.02
0
0
0
0
0

3.36
2.51
1.40
0
0
0

0
0
2.07
0
0
0
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4.2.3 Con-Ins P1, new ILP from injected venom
Con-Ins P1 was identified from the LC-MS/MS analysis of the injected venom from C.
purpurascens. Of the 27 specimens examined, Con-Ins P1 was only identified in the
venom of two snails (Figure 16). Two unique peptides were identified from the RNA
transcript for Con-Ins P1. The A-chain contains 4 cysteines and the B-chain contains 2
cysteines, which form two disulfide bonds to connect the peptides and one intra-peptide
bond on the A chain (Figure 17). Both peptides have multiple PTMs (Figure 17). The Achain peptide contained either 1 or 2 carboxylated glutamates at E5, E15, or both. The Bchain was identified with or without hydroxylated proline (P15), deamidated asparagine
(N21), and C-terminal amidation. C-terminal truncation occurred on the B chain resulting
in peptides ending in either amidated A23 or G24.
When compared to other vertebrate-like conoinsulins that have demonstrated activity
at the human insulin receptor (Con-Ins K1, Con-Ins G1, Con-Ins-T1), Con-Ins P1 shows
the most sequence homology to Con-Ins K1, and very little homology to G1 and T1, aside
from a conserved insulin cysteine residues (Figure 18). All four conoinsulins maintain a
carboxylated glutamate (E) residue; however, this is located at E5 in Con-Ins P1 and E4
in the other three peptides. Con-Ins P1 has a second site of carboxylation at E15 and
lacks the amidated C-terminal. Vertebrate insulins from human and zebrafish also contain
2 glutamate acid residues in the A-chain, but carboxylation is only found in cone snail
venom ILPs.
The Con-Ins P1 B-chain peptide demonstrates even more sequence diversity between
other Conus species and vertebrate homologs. It lacks an N-terminal tail but maintains an
extended C-terminus that is lost in the other venom ILPs. The C-terminal extension
contains an oxidated proline at P15, a deamidated asparagine at N21, and an amidated
C-terminus. Interestingly, the oxidated residue at P15 occurs at the predicted site for
insulin receptor binding, based on previous Con-Ins modeling studies [154]. Con-Ins P1
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is unique from the other characterized conoinsulins in that it contains an extended Cterminus, similar to human and zebrafish insulin, however, the P1 B-chain tail lacks the
functional aromatic triplet, FFY, res ponsible for receptor recognition and dimerization.

Figure 16- Con-Ins P1 from the injected venom of two C. purpurascens
specimens.

Figure 17- Con-Ins P1 modifications identified by MS/MS. PTM symbols: γ=
carboxylated glutamic acid, O= hydroxylated proline, N= deamidated asparagine, *
= amidated C-terminal.
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Figure 18- Con-Ins P1 displays cysteine framework homology to vertebrate
insulins. Sequence comparison between Con-Ins P1, human and zebrafish
insulin, and other previously described conoinsulins. Residues involved in
dimerization are underlined. Homolgy to human insulin shown in blue. PTM
symbols: γ= carboxylated glutamic acid, O= hydroxylated proline, N= deamidated
asparagine, * = amidated C-terminal.

4.3

Discussion
Con-Ins P1 from C. purpurascens is the first conoinsulin identified directly from injected

venom. C. purpurascens hunts using a hook-and-pull strategy that allows for direct
collection of the venom without dissecting the venom duct. Until now, proteomic evidence
of conoinsulins in venom has been limited to Con-Ins G1 and Con-Ins G3 from the venom
gland of C. geographus. In contrast to the hook-and-line strategy employed by C.
purpurascens, C. geographus uses a net-hunting strategy in which the snail expel venom
into the water through their expanded rostrum or ‘net’ to immobilize the fish, and then
rapidly engulf their prey [112]. Because of the challenge of collecting venom through the
net-capture strategy, the conoinsulins identified from C. geographus came from venom
extruded from the dissected venom gland. Dissected venom is inherently more complex;
it includes many protein-processing enzymes and extra components that do not ultimately
end up in the true injected venom that is utilized by the snail against prey. Other vertebratelike conoinsulin sequences from fish-hunting species C. tulipa and C. kinoshitai were
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identified from RNAseq data and lacked proteomic evidence of their composition in the
venom. For these reasons, the indication of ‘weaponized’ venom insulins remained
unsubstantiated, despite evidence of their activity on human insulin receptors [154]. Our
identification of Con-Ins P1 provides the first solid evidence that conoinsulin is actually
injected into the prey, indicating that it plays a physiological role in prey capture.
The identification of conoinsulins at the proteomic level has been limited and most of
them have been found at the transcript level within the venom ducts. When considering
the unreviewed InterPro insulin superfamily database, there are 13 (of 67) conoinsulin
transcripts that exhibit a cysteine framework resembling vertebrate insulin peptides rather
than MIPs and other invertebrate insulins. These 13 vertebrate-like conoinsulins come
from fish-hunting species, C. geographus, C. kinoshitai, and C. tulipa, and worm-hunting
species C. lenavati. The presence of vertebrate-like insulin in the venom duct
transcriptome of a worm-hunter contradicts the theory that these insulins have been
‘weaponized’ by piscivorous cone snails. If the theory of weaponized insulin holds, C.
lenavati may be capable of a mixed hunting strategy, switching between fish and worms
depending on what is readily available, but this is speculation. At this point, there is no
proteomic evidence to confirm the presence of conoinsulin in the injected venom of wormhunting snails. Proteomic analysis of the worm and mollusk-hunting cone snails is an area
that is not well-studied and must be investigated to better understand the function of insulin
in the venom/duct.
Another striking observation is the absence of vertebrate-like insulin transcripts in the
venom ducts of other fish-hunting species (i.e. C. bullatus, C. magus, C. striatus, and C.
ermineus). It may be that only some lineages of fish-hunters gained this alternative
function of ILPs by incorporating it in their venom arsenal, or that others have lost this
evolved trait. The absence of vertebrate-like conoinsulin in C. ermineus is especially
interesting, being that it is a close relative to C. purpurascens and that the two species
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exhibit high sequence homology and even overlap in their venom toxins (Grandal et al.
2020, in review). From the venom mRNA data currently available, we cannot conclude
that ‘weaponized’ insulin is unique to fish-hunting species because it is present C. leviteni,
nor can we state that is ubiquitous in fish-hunting cone snails. Furthermore, our current
understanding of venom conoinsulins is based on transcriptomic data of a limited sample
size – in most cases, one or two specimens per species. In this situation, genomic,
transcriptomic, and proteomic data are all critical to deduce how and why these venom
conoinsulins evolved.
Venom conoinsulins are likely the result of gene duplication and diversification. Such
is the case with lactrodectins, neuropeptide hormone homologs recruited into the venom
by various arthropod taxa [145, 146], and glucagon-like peptides from lizard venom [164].
Evidence for this in cone snails lies in the heterogeneous expression of different ILPs in
different tissue types. This has been shown previously in the net-hunting species C.
geographus [152], and here in the hook-and-pull hunter C. purpurascens. In both cases,
venom conoinsulins have higher expression rates than endogenous MIPs, but this high
expression was limited to venom duct and venom bulb tissue. Con-Ins P1 (venom insulin)
was also expressed in the proboscis and eye tissue where its function remains in question.
The other two conoinsulins identified from C. purpurascens (Con-Ins P3 and P4) more
closely resemble MIPs rather than vertebrate insulins. We found that Con-Ins P3 and P4
had much lower expression than Con-Ins P1, but the expression patterns between the two
differed. Con-Ins P3 was expressed in the venom duct, bulb, and eye, while Con-Ins P4
expression was limited to the eye. Con-Ins P2 resembles a hybrid ILP, its signal peptide
and A-chain sequence show 100% homology to Con-Ins P1, while its B-chain is more
similar to Con-Ins P3, P4, and other MIPS. Con-Ins P2 may be key to our understanding
of conoinsulin diversification and the evolution of venom insulins from endogenous MIPs.
Lymnaea stagnalis’ MIPs are produced and secreted by neuroendocrine glands and are
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important for growth, metabolism, and other processes of neurodevelopment [137, 165];
however, their role in Conus venom is unclear. They may be part of endogenous signaling
mechanisms, or cone snails may utilize these molluscan-type insulins in their venom to
interrupt the cellular processes of their molluscan prey. Although we don’t know why some
species express these vertebrate-like venom insulin peptides and others don’t, the new
evidence of conoinsulins in injected venom supports the model of insulin weaponization
through gene diversification.
Con-Ins P1 is unique from all previously identified conoinsulins in that we have
identified differential modes of PTMs determined by MS/MS spectral matching. Previously,
the synthetic modified version of Con-Ins G1 showed more activity at the human insulin
receptor than the PTM-free peptide [153]. Since Con-Ins P1 contains different
modifications at different positions than G1, it will be important to assess the effect of its
different modified forms for their ability to bind and activate the insulin receptor. It will be
especially important to assess the effect of hydroxylated P15 residue on the C-terminus
of Con-Ins P1 because it is located in the predicted functional site for Con-Ins activity
based on previous molecular docking studies [154].
Con-Ins P1 is also unique from other vertebrate-like conoinsulins in that it lacks the Nterminal tail on the B-chain but maintains an elongated C-terminus, also found on human
and zebrafish insulins. The C-terminus of the B-chain in human insulin includes the
aromatic triplet, known to be critical to the binding mechanism [166]. A recently developed
minimized insulin analog, based on the framework of Con-Ins G1, mini-Ins, maintains
binding activity despite lacking the C-terminus region of the B-chain [155]. This, along with
the proven activity of conoinsulins, is evidence that the aromatic triplet is not essential for
conoinsulin function. However, since the B-chain C-terminal has significant structural
implications for binding, Con-Ins P1 may provide insight into new mechanisms for ligandreceptor interaction
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Molecular docking studies for vertebrate-like conoinsulins reported six conserved
residues within the bioactive conoinsulins: Glu4, Lys/Arg9, and Ser12 in the A-chain and
Ser9, Glu/Asp10, and Glu/Asp17 in the B-chain [154]. Con-Ins P1 only has one of these
six conserved residues, emphasizing its uniqueness among the vertebrate-like venom
insulins. The one conserved residue is aspartate at site B10, consistent with both Con-Ins
T2 and T3, while the others have glutamate, which is predicted to be carboxylated. Human
insulin has a histidine at site B10 that is thought to be involved in receptor recognition and
activation. Amino acid substitution studies have shown that replacing this histidine with an
aspartate increases the peptide’s activity by 4-5 fold, presumably due to the negatively
charged residue [167]. This mutated peptide was developed into a rapid-acting insulin
analog but it was discontinued due to mitogenicity [168, 169]. All vertebrate-like venom
insulins identified thus far contain a negatively charged residue (i.e. histidine) at position
B10. Con-Ins P1, however, also maintains the following three residues (LeuB11, ValB12,
and GluB13) that are identical to human insulin. For these reasons Con-Ins P1 makes an
interesting case study for molecular dynamics, using Con-Ins P1 as a model.
The discovery of vertebrate-like conoinsulins from cone snail venom has opened the
door to the development of novel insulin analogs, like mini-Ins. The uniqueness of ConIns P1 compounded by its presence in injected venom makes this peptide a prime
candidate for drug development. The first step is to use model the molecular dynamics
using advanced cryo-EM structures of the insulin receptor [170-172]. We can use this
information to deduce critical residues for binding and assess the effects of individual
PTMs, as well as single amino acid mutations. These molecular modeling studies can
advance our current understanding of human insulin-receptor interaction and provide
grounds for developing novel, high-efficiency insulin analogs as complementary therapies
for hyperglycemic metabolic conditions.
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5.1

Introduction
Alpha-conotoxins are inhibitors of the nAChR and are the most ubiquitous venom

components across the Conus genus; all species analyzed express one or more αconotoxins in their venom [100]. Unique from other nAChR ligands, α-conotoxins exhibit
subtype selectivity, specifically among neuronal receptor subtypes [52, 55]. Selective
ligands of nAChR subtypes are clinically important probes for studying the
pathophysiology behind diseases like addiction, cognitive disorders, neurodegenerative
diseases, and pain [48, 173, 174]. Subtype specificity makes α-conotoxins valuable
molecular probes for basic neuroscience research and drug design.
The framework I α-conotoxins belong to the A Superfamily, as defined by a conserved
gene signal sequence. This is the largest group of characterized α-conotoxins with the
greatest diversity in subtype selectivity. The post-translational modifications commonly
found on these conotoxins (C-terminal amides and hydroxyprolines) are important for
peptide stability and bioactivity [51]. Within the framework I α-conotoxins, there is
significant diversity in amino acid composition and the size of the inter-cysteine loops. The
size of the α-conotoxin inter-cysteine loops has been shown to affect affinity toward either
muscular or neuronal nAChR subtypes (Figure 3) [53, 54], and can therefore be used to
predict the target of uncharacterized toxins based on homology. In general, α-conotoxins
exhibiting a 3/5 inter-cysteine loop pattern are inhibitors of neuromuscular junction
subtypes, and 4/3 and 4/7 toxins inhibit neuronal subtypes [55].
Neuronal subtypes are expressed heterogeneously throughout the central nervous
system [56]. The most widely expressed subtype in the mammalian brain, α4β2, is heavily
involved in the dopaminergic pathway and nicotine addiction. This receptor can exhibit
different subtype stoichiometry; (α4)2(β2)3 is more sensitive to nicotine than (α4)3(β2)2 [57].
Because of its role in nicotine addiction, α4β2 is the clinical target for smoking cessation
therapies, including the partial agonist, varenicline (Chantix, Pfizer, Inc.). Very few α59

conotoxins inhibit α4β2 but not exclusively, α-GID being the most potent inhibitor [58]. The
α3β4 subtype is the predominant nAChR in the sensory and autonomic ganglia neurons
and is expressed in the mesolimbic dopamine circuitry of the midbrain where it modulates
addiction to nicotine and potentially other drugs of abuse [61, 62]. Only α4/6- conotoxins
α-AuIB and α-TxID have demonstrated specificity for this subtype [63, 175].
The α6-containing subtypes are also expressed abundantly in the midbrain
dopaminergic neurons and are mediators of the addiction reward pathway [65, 66, 176,
177]. Ligands with selectivity for α6-subtype nAChRs are important molecular probes to
study the pathophysiology of addiction and other dopamine-related disorders, such as
Parkinson’s disease. However, α6 selectivity is rare because of its high homology with the
α3 subunit. There is one α6-biased ligand known thus far from C. purpurascens, α-PIA,
which preferentially inhibits α6-containing receptors with 75-fold greater affinity than α3
receptors [67, 68].
Homomeric α7 nAChRs are a unique subtype expressed throughout the brain,
including the hippocampus and cerebral cortex involved in learning and memory [71], as
well as in non-neuronal tissues, like immune cells [70]. Along with a6 receptors, α7
receptors are involved in nicotine reward pathways and present molecular targets for
smoking cessation therapeutics [178-180]. The α7 subtype is also involved in pain and
inflammation pathways [174, 181]. Ric-3 is an important assembly protein found to
increase the assembly and expression of α7 receptors [182] and is therefore co-expressed
with the α7 subunit in this study for functional assays. Several structure-activity studies
with α4/7-conotoxins have identified critical residues for α7 activity [183-185].
The ligand-binding properties of nAChRs have been studied using the X-ray crystal
structure of the soluble acetylcholine binding protein (AChBP) of mollusks Lymnaea
stagnalis and Aplysia californica [43, 186]. AChBPs are not functional ion channels,
however, they form stable homopentamers that preserve features of the ligand-binding
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domain of nAChRs, and thereby serve as useful binding models for α-conotoxins [186,
187]. The AChBP is particularly useful for the homology modeling of the homopentameric
α7 subtypes [160, 188].
There are several previously characterized α-conotoxins from the venom of C.
purpurascens. Framework IV toxin, α-PIVA, is a paralytic nAChR antagonist selective for
muscle-subtype receptors. It is present in the venom in differentially modified forms,
including multiple sites of proline hydroxylation, which affects bioactivity [189]. The
characterized framework I toxins from C. purpurascens include α-PIA, α-PIB, and α-PIC.
Both α-PIB and α-PIC target muscle receptor subtypes [160, 190], while α-PIA is selective
for α6 containing neuronal receptors [191].
Here, we will focus specifically on the framework I α-conotoxins because they 1) have
a conserved two-disulfide bonding pattern (1-3, 2-4), and 2) are relatively small peptides
(<22 residues). These characteristics simplify solid-state peptide synthesis for functional
assays. First, we considered α-conotoxins identified from the injected venom of C.
purpurascens. These included α6-selective conotoxin, α-PIA, and newly identified α-PID
(Grandal et al. 2020, in review). Both peptides exhibit a 4/7 inter-cysteine loop size and
significant sequence homology. We also evaluated venom duct transcriptomic data from
other Conus species for expression of α-conotoxins. Two α4/4- conotoxins, α-NuxI from
Conus nux and α-CedI from Conus cedonulli, were also synthesized for functional
screening. Here, we propose to test the inhibitory activity of three novel α-conotoxins, αPID, α-NuxIA, and α-CedIA, as well as previously described α-PIA. We predict they will be
selective for neuronal subtypes over neuromuscular nAChRs based on their inter-cystine
loop size.

61

5.2

Results:

5.2.1 Bioinformatic approach to identifying novel α-conotoxins
A conserved A superfamily signal sequence was used to identify putative α-conotoxin
transcripts from the transcriptomes of 17 Conus species. The BLAST search returned a
total of 57 transcripts, from which we predicted the mature α-conotoxins sequences
(Figure 19). The search included some previously characterized α-conotoxins, including
α-SI (C. striatus), α-SrIB (C. spurius), α-RgIA and α-RgIB (C. regius), and α-PIC (C.
purpurascens).
All the sequences share framework I cysteine pattern, CC-(X)m-C-(X)n-C. In these
sequences, the first inter-cysteine loop (m) contained either 3 or 4 residues, while the
second loop (n) contained either 3, 4, 5, 6, 7, or 9 resides, resulting in the following loop
patterns: 3/5, 4/3, 4/4, 4/5, 4/6, 4/7, or 4/9. There is high sequence homology among αconotoxins from different species; in many cases only 1 or 2 residues are different. Six
sequences are expressed in multiple species, including α-PIC from C. purpurascens,
which was also found in C. dalli.
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Figure 19- Sequences of α-conotoxins extracted from Conus venom duct
RNA-seq transcripts.
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5.2.2 Functional screening of novel α-conotoxins on nAChR subtypes
We chose three α-conotoxins from the 57 identified sequences to have synthesized
for functional assays: α-PID from C. purpurascens, α-NuxIA from C. nux, and α-CedIA
from C. cedonulli. We also obtained previously characterized α-PIA from a commercial
source as a positive control for screening assays. Both α-CedIA and α-NuxIA exhibit a 4/4/
loop pattern, while α-PIA and α-PID exhibit a 4/7 loop pattern (Figure 20). α-PIA and αPID have highly homologous sequences, with a one residue difference in the first loop and
a two residue difference in the second loop (82% similarity). Each contains 18 residues,
however, α-PID has a one residue N-terminal deletion and C-terminal elongation
compared to α-PIA. α-NuxIA and α-CedIA contain 15 and 13 residues, respectively, and
very little sequence homology aside from asparagine and proline residues in the first loop
that are consistent across all 4 sequences (46% similarity).
Functional screenings were performed on nAChR subtypes expressed in Xenopus
oocyte vectors. Inhibition of ACh-induced current was measured for the following nAChR
subtypes: human neuronal receptors β3α4β2α6β2, α7, α3β4, α4(2)β2(3), α4(3)β2(2),
α4α5β2, and mouse muscle receptor α1β1δε (Table 4). Screening assays measured αCNTX (1 μM) inhibition of ACh-induced current (Figure 21). α-CNTX -elicited responses
were normalized to ACh control currents so that inhibition values represent % control.
All four α-conotoxins inhibit the muscle subtype mα1β1δε (Table 10); the most potent
inhibitor at 1 μM was α-NuxIA (0.15 ± 0.01, p= 0.008) with IC50 of 47.4 nM (Figure 22).
The other three elicited ~50% inhibition at 1 μM (Figure 21).
Alpha-PID significantly inhibits neuronal subtypes α3β4 (0.73 ± 0.03, p= 0.001) and
α4(2)β2(3) (0.84 ± 0.02, p= 0.006). α-CedIA also significantly inhibits α4(2)β2(3) (0.90 ±
0.02, p= 0.005), while α-NuxIA significantly inhibits α4(3)β2(4) with alternative
stoichiometry (0.78 ± 0.04, p= 0.002). No significant inhibition was measured on receptor
α4α5β2.
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Both α-PID (0.14 ± 0.02, p= 0.0003) and α-PIA (0.06 ± 0.03, p= 0.055) strongly
inhibited the β3α4β2α6β2 receptor concatemer. These values corresponded to an 86%
inhibition of ACh-induced current by α-PID and 94% inhibition by α-PIA. An inhibitory doseresponse curve (30 nM, 100 nM, 300 nM, and 1μM) calculated an IC50 of 119.7 nM for αPID and 329.9 nM for α-PIA (Figure 23A). α-PIA exhibited a greater response at higher
concentrations (1 μM and 300 nM), while α-PID exhibited a greater response at lower
concentrations (100 nM and 30 nM) (Table 11). The β3α4β2α6β2 receptor was also
significantly inhibited by 1 μM α-CedIA (0.74 ± 0.02, p= 0.031), although to a lesser extent
than α-PIA and α-PID. α-NuxIA also demonstrated minor inhibition on β3α4β2α6β2,
although not significant (0.78 ± 0.07, p= 0.294).
Alpha-PID also significantly inhibited α7 receptors at 1 μM (0.35 ± 0.05, p= 0.057) and
300 nM (0.54 ± 0.05, p= 0.029) (Table 11, Figure 23B).

Table 9- Inhibitory activity of Framework I α-conotoxins from C. purpurascens.
α-CNTX
α-PIA

Sequence
-RDPCCSNPVCTVHNPQIC

Reference
This work

α-PIB

QSPGCCWNPACVKNR---C

Lopez-Vera (2007)

nAChR selectivity
hβ3α4β2α6β2* >> mα1β1δε >> hα4(3)β2(2) >
hα4(2)β2(3) > hα4α5β2 ≈ hα3β4 > hα7
rα6/α3β2β3 > rα6/α3β4 > rα3β2 > rα3β4 >> rα4β2
hα6/α3β2β3 > hα6/α3β4 >> hα1β1δε
mα1β1δε ≈ mα1β1δγ

α-PIC

--SGCCKHPACGKNR---C

Hoggard (2017)

rα1β1δε > rα1β1δγ ≈ hα3β2 >> hα7

α-PID

--DPCCSNPACNVNNPQICG

this work

hβ3α4β2α6β2* > hα7 > mα1β1δε > hα3β4 >
hα4(2)β2(3) > hα4(3)β2(2) ≈ hα4α5β2

Dowell (2002)

Figure 20- Sequences of the α-conotoxins tested for inhibitory activity.
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Figure 21- Inhibitory activity of α-PIA, α-PID, α-NuxIA, and α-CedIA on
nAChR subtypes. *P-value ≤ 0.05

Table 10- Inhibitory activity of α-PIA, α-PID, α-NuxIA, and α-CedIA on nAChR
subtypes. Values represent % ACh- elicited response ±SEM (n). p-values calculated by
a paired t-test.
α1β1δε
α3β4
α4(2)β2(3)
α4(3)β2(2)
α4α5β2
α7
α4α6β2β3

α-PID
0.59 ± 0.03 (8)
p= 0.025
0.73 ± 0.03 (4)
p= 0.001
0.84 ± 0.02 (8)
p= 0.006
0.91 ± 0.06 (4)
p= 0.129
0.91 ± 0.06 (4)
p= 0.112
0.35 ± 0.05 (4)
p= 0.057
0.14 ± 0.02
(19)
p= 0.0003

α-PIA
0.52 ± 0.06 (5)
p= 0.093
0.96 ± 0.07 (3)
p= 0.266
0.91 ± 0.02 (4)
p= 0.802
0.84 ± 0.08 (4)
p= 0.120
0.94 ± 0.13 (3)
p= 0.316
1.09 ± 0.18 (4)
p= 0.380
0.06 ± 0.03 (4)
p= 0.055
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α-NuxIA
0.15 ± 0.01 (4)
p= 0.008
0.90 ± 0.02 (3)
p= 0.066
0.95 ± 0.19 (8)
p= 0.298
0.78 ± 0.04 (4)
p= 0.002*
0.90 ± 0.09 (4)
p= 0.201
0.94 ± 0.10 (4)
p= 0.257
0.78 ± 0.07 (3)
p= 0.294

α-CedIA
0.57 ± 0.04 (4)
p= 0.046
1.16 ± 0.11 (3)
p= 0.145
0.90 ± 0.02 (8)
p= 0.005
0.91 ± 0.04 (4)
p= 0.137
0.98 ± 0.15 (4)
p= 0.234
0.97 ± 0.19 (4)
p= 0.336
0.74 ± 0.02 (4)
p= 0.031

Figure 23- Dose response curve for α-PIA and α-PID on α4α6β2β3 and α7 nAChRs.
Error bars represent ± SEM

Figure 22- Dose response curve for α-NuxIA on α1β2δε nAChRs.
Error bars represent ± SEM

67

Table 11- Dose-response of α-PIA and α-PIDc on α4α6β2β3 and α7 nAChRs.
Values represent % ACh- elicited response ±SEM. p-values calculated by a paired
t-test.
[α-CNTX]
1 μM
300 nM
100 nM
30 nM

α4α6β2β3
α-PID
0.14 ± 0.02
p= 0.0003
0.36 ± 0.04
p= 0.002
0.53 ± 0.02
p= 0.025
0.88± 0.07
p= 0.166

α-PIA
0.06 ± 0.03
p= 0.055
0.24 ± 0.03
p= 0.006
0.95 ± 0.10
p= 0.439
0.93± 0.08
p= 0.199

α7
α-PID
0.35 ± 0.05
p= 0.057
0.54 ± 0.05
p= 0.029
0.82 ± 0.17
p= 0.215
----

α-PIA
1.09 ± 0.18
p= 0.380
0.97 ± 0.30
p= 0.491
1.25 ± 0.34
p= 0.317
----

Figure 24- Alignment of α-PID and α-PIA with conotoxins that inhibit α7 receptors.

5.2.3 Modeling α-PID and α-PIA binding to the α7 nAChR
Homology modeling was used to model the extracellular domain of the human α7
receptor based on the structure of Aplysia AChBP bound to α-LvIA (PDB: 5XGL) [192]. By
replacing α-LvIA with α-PIA and α-PID, we were able to model and compare their binding
dynamics to the α7 homopentamer. The models contain five α-CNTX molecules bound
between each adjacent subunit (Figure 25A). Each of the five bound α-CNTX was
analyzed for contacts, in the form of hydrogen bonds, with the principal (p) and the
complementary (c) receptor subunits (Figure 25B). All possible sites of contacts combined
from the five bound α-CNTXs are summarized in Figure 25C. α-PID had seven residues
in contact with the c subunit (P2, C4, S5, N10, V11, C17, and G18), three residues in
contact with the p subunit (N6, P7, N13), and one residue with contact to both (N12). α68

PIA had four residues in contact with the c subunit (R1, D2, N7, N14), two residues in
contact with the p subunit (S6, C18), and two residues in contact with both (T11, V12).
Overall, α-PID showed more possible interactions (10 residues) compared to α-PIA (8
residues).

Figure 25- Model of α-PID bound to human α7 receptor. A) α-PID (red) bound at all
five binding sites and B) α-PID (red) in the binding pocket between two adject α7
subunits, the principal (p) subunit (purple) and the complimentary (c) subunit (green).
This model used the structure of α-LvIA bound to the AChBP (PDB: 5XGL) as a
template. C) α-PID and α-PIA residue contacts with the hα7 receptor determined by
molecular energy and distance calculations. Contacts are color coded by the following:
black= c subunit, red= p subunit, green= both c and p subunit contacts.

5.3

Discussion
Alpha- conotoxins are venom peptides that selectively bind and inhibit nAChRs. Their

role in cone snail venom is analogous to that of α-bungarotoxins in snake venom, to block
neurotransmission at the postsynaptic membrane in the neuromuscular junction, thereby
immobilizing prey. What sets α-conotoxins apart from other nAChR ligands is their unique
affinity for neuronal nAChR subtypes, which are not involved in muscle movement, but
rather are highly involved in neurotransmitter signaling processes in the brain. It is not
known whether cone snails have evolved to target receptors homologous to vertebrate
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neuronal receptors in their invertebrate prey [193], or if the neuronal subtype specificity is
an anomaly that happens to be to our benefit, as these neuronal subtypes contribute to
the pathophysiology of many devastating human diseases [181].
Neuronal nAChR subtypes include all subunit arrangements other than the muscle
subtype, α1β1(δ/γ/ε). In this study we screened a subset of human neuronal receptor
subtypes: β3α4β2α6β2, α7, α3β4, α4(2)β2(3), α4(3)β2(2), and α4α5β2. Alpha-conotoxin
selectively has been broadly attributed to the inter-cysteine loop sizes of these small
disulfide-constrained peptides. Muscle-subtype selectivity is commonly found in α3/5
conotoxins (3 and 5 residues in the first and second inter-cysteine loops), while α4/3, α4/4,
and α4/7 conotoxins tend to inhibit neuronal subtypes. Here, we screened two new α4/4
conotoxins (α-NuxIA and α-CedIA) identified from RNA sequencing, and two α4/7
conotoxins (α-PIA and α-PID) identified in the injected venom of C. purpurascens (Grandal
et al. 2020, in review). α-PIA has been previously described as an α6-selective conotoxin
with the unique ability to distinguish between the similar α3 and α6 subunit, (Table 9) [67].
We aimed to validate these previous findings and expand the functional screening to
include α7 receptors. We predicted that all four α-conotoxins would show preferential
inhibition toward neuronal subtypes over neuromuscular receptors, based on their intercysteine loop sizes.
The results from the screening assays showed that all four α-conotoxins did not exhibit
selectivity for neuronal subtypes. The first notable finding from this body of work is that all
four α-conotoxins showed inhibition of the muscle subtype, mα1β1δε, by at least 40%. It
is well supported that α3/5 conotoxins have a high affinity for the muscle subtype of the
nicotinic receptor [50], but we did not expect to see α1β1 inhibition by α4/7 conotoxins,
based on previously characterized α-conotoxins [53, 54]. This is also in stark contrast to
previous functional assays with α-PIA on hα1β1δε receptors, where 10μM (10x our
screening concentration) α-PIA did not affect inhibition. This could be due to the
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discrepancy in the species cDNA, as previous studies used human receptors [67], and
here we used mouse muscle receptors. The strongest inhibition of mα1β1δε muscle
receptors detected in this study was demonstrated by α4/4 conotoxin, α-NuxIA, (IC50= 47
nM). Existing data on α4/4 conotoxin subtype specificity is limited; however, two α4/4
conotoxins have been identified from C. purpurascens (α-PIB and α-PIC). Both conotoxins
also showed high affinity for muscle α1β1δε receptors over neuronal subtypes (Table 9)
[160, 190]. Although α-NuxIA shows little sequence homology to α-PIB or α-PIC, the
combined evidence suggests that the α4/4 framework conotoxins, like the α3/5
conotoxins, are selective for neuromuscular nicotinic receptors.
The second strongest inhibition was on the α6-containing concatemer, hβ3α4β2α6β2
by both α-PIA (329 nM) and α-PID (119 nM). At the highest concentration (1 μM) α-PIA
shows greater inhibition than α-PID (96% vs 84%), but at lower concentrations (100 nM
and 30 nM) α-PID has a stronger effect, resulting in a lower IC50 value than α-PIA.
Previous studies report a much lower IC50 (1.7 nM) for α-PIA on hα6/α3β2β3 receptors
[67]. However, we cannot make a direct comparison to these studies because we used an
α6 concatemer in this screening study that contained α6 and α4 subunits (β3α4β2α6β2),
while previous studies used an α6/α3 chimeric receptor. Because α6 and α3 are highly
homologous structures, this likely explains the stronger inhibition by α-PIA, as it is much
more selective for α6/α3 than for α4. Interestingly, both α-NuxIA and α-CedIA also
inhibited the hβ3α4β2α6β2 receptor (~25% inhibition), although to a much lesser extent
than α-PIA and α-PID.
The finding that both α-PIA and α-PID conotoxins inhibited α6 receptors is not
altogether surprising since they share 84% homology. More surprising was their drastic
difference in affinity for the homomeric neuronal α7 receptor. α-PIA did not affect the hα7
receptors, while α-PID exhibited strong inhibition (65% at 1μM). When comparing to other
α4/7 conotoxins with α7 receptor activity (Figure 24), there is significant sequence
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homology within the loops. Because the two share 82% identity, they present an excellent
case for comparing binding dynamics on the α7 receptor. Therefore, we employed
homology modeling to construct a human α7 model and predict molecular interactions
between α-PIA/ α-PID in the binding domain.
The hα7 extracellular binding domain bound to α-PIA/α-PID was modeled based on
the structure of the AChBP bound to the conotoxin α-LvIA. The resulting models provided
information on the molecular interactions of α-PIA and α-PID with the α7 receptor. Despite
their sequence homology, the two conotoxins exhibit very different binding dynamics.
Previous AChBP binding studies suggest that α-CNTX inhibitory activity is a result of
interaction with the C loop located on the principal subunit. This was the case with the
potent α7 blocker, α-PnIA, which upon binding locked the C loop in a resting state
conformation rendering it unable to be activated [186]. Both the α-PIA and α-PID models
had more interactions between the complementary subunit than the principal subunit.
However, α-PID has three residue contacts with the principal subunit that are not present
in the α-PIA model. These hydrogen bonds occur at positions N6, P7, and N13, and may
be involved in α-PID inhibition of hα7. It is important to note that while α-CNTX interactions
with the principal subunit are assumed critical for nAChR inhibition, interactions with the
complementary subunit may also play a role. Going forward, amino acid substitution
experiments with α-PIA and α-PID could be used to confirm the critical residues for α7
activity.
Alpha conotoxins have been studied for decades to examine their selective binding to
nAChRs. These studies, however, have been primarily screens of a single α-conotoxin
after isolation from the venom or through cDNA libraries. Here we demonstrate how
advances in sequencing technology aid large-scale prediction of novel α-conotoxin
sequences, allowing us to choose sequences based on amino acid composition and loop
size to further dissect the underpinnings for nAChR subtype selectivity.
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CHAPTER 6:
CONCLUSIONS AND FUTURE DIRECTIONS
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6. Conclusions and Future Directions
The therapeutic application of venom peptides has been known for centuries [194].
The use of venom for medicinal purposes is far from a new notion, however, modern
advances in molecular technologies have revolutionized venom studies. Natural product
discovery, specifically natural peptide discovery, has evolved tremendously due to nextgeneration sequencing. Genomic data 1) enables large-scale venom protein/peptide
discovery and 2) allows us to study the evolution of venom genes across venomous
phylogenies. In this body of work, we have capitalized on venomics methodologies to
identify cone snail venom peptides with therapeutic potential. Our venomic approach
merged transcriptomic and proteomic workflows to interrogate the venom of 17 Conus
species, focusing on the fish-hunting cone snail, C. purpurascens.
We used top-down, high-resolution MS/MS analysis and venom duct
transcriptome databases to analyze the injected venom of C. purpurascens. We described
33 conopeptides and all of their associated toxiforms. Twenty-one of these venom
peptides (64% of the identified components) were identified here for the first time. Of these
new conopeptides was PVIIIA, a five disulfide-bonded conotoxin that was abundant in
85% of the injected venom samples, and therefore likely plays an important role in the
venom. Comparison of the venom profiles across 27 specimens showed that the venom
peptides clustered into two possible profiles with distinct molecular targets. The results
provide insight into the probable pharmacological targets of newly identified venom
peptides.
We also described a new conoinsulin from the venom of C. purpurascens, ConIns P1. This is the first ILP identified directly from injected venom, supporting previous
evidence of ILP incorporation into the venom. Con-Ins P1 is unique from other
conoinsulins in that it displays a different PTM profile and varies drastically in the C-chain
sequence/ structure. We hypothesize that the sequence of the B chain C-terminal will
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allow it to maintain activity at the insulin receptor but will not lend to self-association of
Con-Ins P1 peptides, as self-association of human insulin decreases its bioactivity. Going
forward, we will delve into the molecular dynamics and function of Con-Ins P1. First, we
will model the Con-Ins P1 peptide using Con-Ins G1 as a template [153], then we will
model the dimerization of Con-Ins P1 to assess the dimer stability. We will also model
binding dynamics at the human insulin receptor to test our hypothesis. Based on modeling
studies, we plan to synthesize the peptide in differentially modified forms for functional
assays.
The venomic approach employed in this study resulted in the identification of a
diverse range of conopeptides with different cysteine frameworks and potential
pharmacological targets (Table 1, Table 5). We decided to focus on the α-conotoxins for
functional characterization due to their relative ease of synthesis to obtain large quantities.
The α-conotoxin family of peptides has well-defined cystine connectivity, and the ones we
had synthesized for this study were small (α-CedIA-13 residues, α-NuxIA-15 residues, αPID- 18 residues). We screened these toxins, along with commercially purchased α-PIA,
on nAChR subtypes using a Xenopus oocyte expression system and two-electrode
voltage clamp to measure inhibition of ACh-induced current. We found that α-NuxIA was
a potent inhibitor of muscle subtype nAChRs (α1β1δε, IC50= 47 nM). Our results also
supported previous work that α-PIA selectively inhibits α6 receptors. α-PID shares 82%
identity with α-PIA and is a potent inhibitor of both α6 and α7 receptors. Neuronal α6 and
homopentameric α7 play important roles in neurological and neurodegenerative diseases,
as well as addiction [179, 181]. Selective ligands for specific nicotinic receptors are critical
for dissecting the pathophysiology of individual subtypes. Using molecular homology
modeling we set out to find the discriminating factor for α7 selectivity. α-PIA and α-PID
binding to the hα7 receptor was modeled based on the AChBP-α-LvIA structure, allowing
analysis of molecular interactions between bound α-CNTX and receptor. This analysis
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revealed three α-PID residues in contact with the principal receptor subunit that may
explain increased α-PIA selectivity toward hα7 over α-PIA. Further amino acid substitution
functional assays are required to test the critical nature of these residue interactions.
Scientists have historically, and will continue to look towards nature for the answer
to medical questions. This body of work demonstrates how venomic methods
(transcriptomics, proteomics) advance traditional natural product discovery techniques. In
the case of cone snails, millions of years of evolution have engineered libraries of bioactive
peptides with high selectivity for clinically important molecular targets. We have
sequenced, assembled, and mined their genetic information to harness their venom
evolution for our medical advantage. The tight disulfide constrained nature of many
conopeptides, such as the cysteine knot peptides, has been shown to increase thermal
and proteolytic stability, both important for developing successful drugs. However, there
are obstacles and limitations when developing peptides as drugs.
The largest obstacle we face in developing venom proteins/peptides as
pharmaceutics is their inherent inability to cross biological membranes, such as intestinal
walls or the blood-brain barrier. In the case of Prialt®, which requires an intrathecal pump
for administration, we see how delivery techniques can limit the indication of a drug and
can cause potential secondary health effects. Peptide engineering methods for increasing
peptide permeation through biological membranes include cyclization and glycosylation
[11, 12]. Some conopeptides are naturally glycosylated, such as the analgesic neurotensin
analog, contulakin-G [195]. Based on this, cono-glycopeptides may make good drug
candidates, however, these peptides are commonly linear, leaving them susceptible to
proteolysis. Some peptide therapeutics can be successfully administered by systemic
injection, such is the case for insulin and the venom derived diabetes drug, exenatide
[196]. This has positive indications for future conoinsulin analogs which are currently being
developed [155].
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Taken together, it could be argued that the value of venom research in drug
discovery is in studying the molecular interactions and binding dynamics of the naturally
engineered, highly selective ligands with clinical receptor targets. The large libraries of
bioactive molecules provided by venomics approaches allow us to distinguish the critical
residues and receptor interactions necessary for maximal response. Venom peptides
thereby provide the tools to develop specific and effective mimetic drugs for a range of
neuropathologies (i.e. pain, addiction, neurodegenerative diseases, neuroendocrine
disorders). As we continue to understand the value of peptides and biologics as
therapeutics, we will need to promote engineering efforts toward improved drug delivery
mechanisms.
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APPENDIX A: Toxiforms and sites of modification for each conopeptide identified
from the injected venom of C. purpurascens

Table 12- α-PIA toxiforms
α-PIA

R

R

D

P

C

C

S

N

O

P

V

C

T

V

H

O

Annotated Sequence
CCSNPVCTVHNPQIC*
PCCSNPVCTVHNPQIC*
PCCSNPVCTVHNPQICG*
DPCCSNPVCTVHNPQIC*
DPCCSNPVCTVHNPQIC
DPCCSNPVCTVHNOQIC*
DPCCSNOVCTVHNPQIC*
DPCCSNPVCTVHNPQICG*
RDPCCSNPVCTVHNPQIC*
RDPCCSNPVCTVHNPQIC
RDPCCSNPVCTVHNOQIC*
RDPCCSNOVCTVHNPQIC*
RDPCCSNOVCTVHNPQIC
RDPCCSNPVCTVHNOQIC
RDPCCSNPVCTVHDOQIC*
RDPCCSNPVCTVHNOqIC*
RDPCCSNOVCTVHNOQIC*
RDOCCSNOVCTVHNPQIC*
RDPCCSNPVCTVHNPQICG*
RDPCCSNPVCTVHNPQICG
RDPCCSNOVCTVHNPQICG*
RRDPCCSNPVCTVHNPQIC*

N

P

Q

D

O

E

R

C

MH+ [Da]
1844.77
1941.82
1998.84
2056.84
2057.83
2072.84
2072.84
2113.87
2212.95
2213.93
2228.94
2228.94
2229.92
2229.93
2229.94
2229.94
2244.94
2244.94
2269.97
2270.96
2285.96
2369.06

Table 13- α-PIB toxiforms
α-PIB

Q
Z

S

P

G

C

O

Annotated Sequence
GCCWNPACVKNRC*
OGCCWNPACVKNRC*
ZSPGCCWNPACVKNRC*
ZSOGCCWNPACVKNRC*

C

W

N

P

A

C

O

V

K

N
D

MH+ [Da]
1680.70
1793.74
1975.82
1991.81
78

*

I

C

G

*

*

ZSOGCCWNPACVKDRC*
ZSOGCCWNOACVKNRC*

1992.79
2007.80

Table 14- α-PIC toxiforms
α-PIC

S

G

C

C

K

P

Annotated Sequence
SGCCKHPACGKNRC

A

C

G

K

N

R

C

Thγo. MH+ [Da]
1691.70

Table 15- α-PID toxiforms
PID

R

D

P

C

C

S

N

O

P

A

C

N

V

N

N

O

Annotated Sequence
CCSNPACNVNNPQIC*
PCCSNPACNVNNPQIC*
DPCCSNPACNVNNPQIC*
RDPCCSNPACNVNNPQIC*
RDPCCSNPACNVNNPQIC
RDPCCSNPACNVNNOQIC*
RDPCCSNOACNVNNPQIC*
RDOCCSNOACNVNNPQIC*
RDPCCSNOACNVNNOQIC*
RDPCCSNPACNVNNPQICG
RDPCCSNPACNVNNOEICGRRCSRTLTKTyCOLPD
RDPCCSNPACNVNNPEICGRRCSRTLTKTyCOLOD

P

Q

O

E

I

C

G

*

MH+ [Da]
1806.71
1903.77
2018.79
2174.90
2175.88
2190.89
2190.89
2206.88
2206.89
2232.90
4348.78
4348.79

Table 16- PIE toxiforms
N

A

A

A

K

A

F

D

L

T

A

P

T

A

G

E

G

C

C

O

F

N

P
O

Annotated Sequence
NAAAKAFDLTAPTAGEGCCFNOACAVNNPNIC
NAAAKAFDLTAOTAGEGCCFNPACAVNNPNIC

MH+ [Da]
3412.48
3412.48

Table 17- PIF toxiforms
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A

C

A

N

N

P

N

I

C

PIF

Q

E

P

Z

γ

O

G

C

C

R

N

P

D

O

Annotated Sequence
GCCRNPACVKHRC*
PGCCRNPACVKHRC*
PGCCRNOACVKHRC*
OGCCRNPACVKHRC*
EPGCCRNPACVKHRC*
ZEPGCCRNPACVKHRC*
ZEPGCCRDPACVKHRC*
ZEPGCCRNPACVKHRC
ZEPGCCRNOACVKHRC*
ZEOGCCRNPACVKHRC*
ZEOGCCRNOACVKHRC*
ZγPGCCRNPACVKHRC*
ZγOGCCRNPACVKHRC*
ZγPGCCRNOACVKHRC*

A

C

V

K

H

R

C
*

MH+ [Da]
1673.73
1770.79
1786.78
1786.79
1899.83
2010.86
2011.84
2011.85
2026.86
2026.86
2042.85
2054.85
2070.85
2070.85

Table 18- PIG toxiforms
PIG

P

C

C

S

N

P

V

C

T

V

H

G

G

P

Q

L

C
*

Annotated Sequence MH+ [Da]
CCSNPVCTVHGGPQLC* 1844.77
PCCSNPVCTVHGGPQLC* 1941.82
Table 19- α-PIVA toxiforms
G

C

C

G

S

Y

P

N

B

O

D

A

A

C

H

P

C

S

C

K

O

D

R

P
O

Annotated Sequence
GCCGSYPNAACHPCSCKDRPSYC
GCCGSYPDAACHPCSCKDRPSYC
GCCGSYPNAACHPCSCKDROSYC*
GCCGSYPNAACHPCSCKDROSYC
GCCGSYPNAACHOCSCKDRPSYC
GCCGSYPDAACHOCSCKDRPSYC
GCCGSYPDAACHPCSCKDROSYC

MH+ [Da]
2764.03
2765.03
2779.03
2780.02
2780.02
2781.00
2781.02
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S

Y

C

G

Q

G

*

*

E*

*

GCCGSYONAACHOCSCKDRPSYC*
GCCGSYONAACHOCSCKDRPSYC
GCCGSYPNAACHOCSCKDROSYC
GCCGSYODAACHOCSCKDRPSYC
GCCGSYONAACHOCSCKDROSYC
GCCGSYODAACHOCSCKDROSYC
GCCGSYPNAACHPCSCKDRPSYCG
GCCGSYPNAACHPCSCKDROSYCG
GCCGSYPNAACHOCSCKDRPSYCG
GCCGSYPDAACHPCSCKDROSYCG
GCCGSYPDAACHOCSCKDRPSYCG
GCCGSYPNAACHOCSCKDROSYCG
GCCGSYONAACHOCSCKDRPSYCG
GCCGSYONAACHOCSCKDROSYCG
GCCGSYODAACHOCSCKDROSYCG
CCGSYPNAACHPCSCKDRPSYCGQ**
CCGSYPNAACHOCSCKDRPSYCGQ*
CCGSYONAACHPCSCKDRPSYCGQ*
CCGSYPNAACHPCSCKDROSYCGQ*
CCGSYPDAACHPCSCKDROSYCGQ*
CCGSYONAACHOCSCKDRPSYCGQ*
CCGSYPNAACHOCSCKDROSYCGQ*
CCGSYODAACHOCSCKDRPSYCGQ*
CCGSYPDAACHOCSCKDROSYCGQ*
CCGSYONAACHOCSCKDROSYCGQ*
GCCGSYPNAACHPCSCKDRPSYCGQ*
GCCGSYPNAACHPCSCKDRPSYCGQ
GCCGSYPNAACHPCSCKDRPSYCGQ*
GCCGSYPDAACHPCSCKDRPSYCGQ
CCGSYPNAACHPCSCKDROSYCGQG*
GCCGSYPNAACHOCSCKDRPSYCGQ*
GCCGSYPNAACHPCSCKDROSYCGQ*
GCCGSYONAACHPCSCKDRPSYCGQ*
GCCGSYODAACHPCSCKDRPSYCGQ*
GCCGSYPDAACHOCSCKDRPSYCGQ*
GCCGSYPNAACHPCSCKDROSYCGQ
GCCGSYONAACHPCSCKDRPSYCGQ
GCCGSYPNAACHOCSCKDRPSYCGQ
GCCGSYPDAACHPCSCKDROSYCGQ*
GCCGSYONAACHPCSCKDRPSYCGQ*
GCCGSYODAACHPCSCKDRPSYCGQ*
CCGSYPNAACHOCSCKDROSYCGQG*
CCGSYONAACHOCSCKDRPSYCGQG*

2795.03
2796.01
2796.01
2797.00
2812.01
2813.01
2821.05
2837.04
2837.04
2838.04
2838.04
2853.03
2853.04
2869.03
2870.03
2891.10
2907.09
2907.09
2907.10
2908.09
2923.09
2923.09
2924.08
2924.09
2939.08
2948.12
2949.11
2950.10
2950.11
2964.11
2964.11
2964.12
2964.13
2965.10
2965.10
2965.11
2965.11
2965.11
2965.12
2966.10
2967.09
2980.08
2980.11
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GCCGSYONAACHOCSCKDRPSYCGQ*
GCCGSYPNAACHOCSCKDROSYCGQ*
GCCGSYPDAACHOCSCKDROSYCGQ*
GCCGSYONAACHOCSCKDRPSYCGQ
GCCGSYPNAACHOCSCKDROSYCGQ
GCCGSYODAACHOCSCKDRPSYCGQ*
GCCGSYONAACHOCSCKDRPSYCGQ*
GCCGSYONAACHOCSCKDROSYCGQ*
GCCGSYODAACHOCSCKDROSYCGQ*
GCCGSYONAACHOCSCKDROSYCGQ
GCCGSYPNAACHPCSCKDRPSYCGQG*
GCCGSYPNAACHPCSCKDRPSYCGQG
GCCGSYPDAACHPCSCKDRPSYCGEG
GCCGSYPNAACHPCSCKDROSYCGQG*
GCCGSYPNAACHOCSCKDRPSYCGQG*
GCCGSYONAACHPCSCKDRPSYCGQG*
GCCGSYPNAACHOCSCKDRPSYCGQG
GCCGSYPNAACHOCSCKDRPSYCGEG*
GCCGSYPNAACHPCSCKDROSYCGQG
GCCGSYPNAACHPCSCKDROSYCGEG*
GCCGSYPDAACHPCSCKDROSYCGQG*
GCCGSYPDAACHOCSCKDRPSYCGQG*
GCCGSYPNAACHPCSCKDROSYCGEG
GCCGSYPNAACHOCSCKDRPSYCGEG
GCCGSYPDAACHOCSCKDRPSYCGEG*
GCCGSYPDAACHOCSCKDRPSYCGQG
GCCGSYPDAACHPCSCKDROSYCGEG*
GCCGSYPDAACHPCSCKDROSYCGQG
GCCGSYONAACHPCSCKDRPSYCGEG
GCCGSYODAACHPCSCKDRPSYCGEG
GCCGSYONAACHOCSCKDRPSYCGQG*
GCCGSYPNAACHOCSCKDROSYCGQG*
GCCGSYPNAACHOCSCKDROSYCGQG
GCCGSYPNAACHOCSCKDROSYCGEG*
GCCGSYONAACHOCSCKDRPSYCGEG*
GCCGSYONAACHOCSCKDRPSYCGQG
GCCGSYODAACHOCSCKDRPSYCGQG*
GCCGSYPDAACHOCSCKDROSYCGQG*
GCCGSYONAACHOCSCKDROSYCGQG*
GCCGSYODAACHOCSCKDROSYCGQG*
GCCGSYONAACHOCSCKDROSYCGEG*
GCCGSYONAACHOCSCKDROSYCGQG
CCGSBONAACHOCSCKDROSYCGQG*

2980.11
2980.11
2981.10
2981.10
2981.10
2981.11
2982.10
2996.11
2997.09
2997.10
3005.14
3006.14
3008.10
3021.14
3021.14
3021.14
3022.12
3022.12
3022.13
3022.13
3022.13
3022.13
3023.12
3023.12
3023.12
3023.12
3023.12
3023.12
3023.12
3024.10
3037.13
3037.13
3038.11
3038.11
3038.12
3038.12
3038.12
3038.12
3053.13
3054.11
3054.12
3054.12
3074.04
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RGCCGSYPNAACHPCSCKDROSYCGQ*
RGCCGSYPDAACHPCSCKDROSYCGQ*
RGCCGSYPDAACHPCSCKDROSYCGQG*
RGCCGSYPNAACHPCSCKDROSYCGEG*
RGCCGSYPNAACHPCSCKDROSYCGQG
GCCGSYPNAACHOCSCKDRPSYCGEGR
GCCGSYPNAACHPCSCKDROSYCGEGR
SHVVRGCCGSYPDAACHPCSCKDROSYCGQ*
SHVVRGCCGSYONAACHOCSCKDRPSYCGQ*
SHVVRGCCGSYPNAACHOCSCKDROSYCGQ*
LLSHVVRGCCGSYONAACHOCSCKDRPSYCGQ*

3120.22
3121.17
3178.19
3178.19
3178.19
3179.20
3179.20
3543.45
3558.44
3558.44
3784.60

Table 20- κ-PIVE toxiforms
R

D

C

C

G

V

K

L

E

M

γ

O

C

H

P
O

Annotated Sequence
DCCGVKLEMCHPCLCDNSCKN
DCCGVKLEMCHPCLCDDSCKN
DCCGVKLEMCHPCLCDNSCKD
DCCGVKLEmCHPCLCDNSCKN
DCCGVKLEMCHOCLCDNSCKN
DCCGVKLEmCHOCLCDNSCKN
DCCGVKLγMCHPCLCDNSCKN
CCGVKLEMCHPCLCDNSCKNY
CCGVKLEMCHPCLCDNSCKNYG
DCCGVKLEMCHPCLCDNSCKNY*
DCCGVKLEMCHPCLCDNSCKNY
DCCGVKLEMCHPCLCDDSCKDY*
DCCGVKLEMCHPCLCDDSCKNY
DCCGVKLEmCHPCLCDNSCKNY
DCCGVKLEMCHOCLCDNSCKDY*
DCCGVKLEMCHOCLCDNSCKNY
DCCGVKLEmCHPCLCDNSCKDY*
DCCGVKLEmCHPCLCDDSCKNY*
DCCGVKLγMCHPCLCDNSCKNY
DCCGVKLγMCHPCLCDNSCKDY*
DCCGVKLEMCHPCLCDNSCKNYG
DCCGVKLEMCHPCLCDDSCKNYG
DCCGVKLEMCHPCLCDDSCKDYG*
DCCGVKLEMCHPCLCDNSCKDYG
CCGVKLEMCHPCLCDNSCKNYGK*

C

L

C

D

N

S

C

D

MH+ [Da]
2657.02
2658.00
2658.00
2673.01
2673.01
2689.01
2701.02
2705.06
2762.07
2819.10
2820.08
2821.07
2821.07
2836.08
2836.08
2836.08
2836.09
2836.09
2864.09
2864.09
2877.10
2878.09
2878.09
2878.09
2889.19
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K

N

Y

G

K

G

D

*

*

*

*

CCGVKLEMCHPCLCDNSCKNYGK
DCCGVKLEmCHPCLCDNSCKDYG*
DCCGVKLEmCHPCLCDNSCKNYG
DCCGVKLEMCHOCLCDNSCKNYG
DCCGVKLEMCHOCLCDNSCKDYG*
DCCGVKLγMCHPCLCDNSCKNYG*
DCCGVKLγMCHPCLCDNSCKDYG*
DCCGVKLγMCHPCLCDNSCKNYG
CCGVKLγMCHPCLCDNSCKNYGK*
DCCGVKLEMCHPCLCDNSCKNYGK*
DCCGVKLEMCHPCLCDNSCKNYGK
DCCGVKLEMCHPCLCDDSCKDYGK*
DCCGVKLEmCHPCLCDNSCKNYGK*
DCCGVKLEMCHOCLCDNSCKNYGK*
DCCGVKLEMCHOCLCDNSCKDYGK*
DCCGVKLEmCHPCLCDNSCKDYGK*
DCCGVKLEmCHPCLCDDSCKNYGK*
DCCGVKLEMCHOCLCDDSCKNYGK*
DCCGVKLEmCHOCLCDNSCKNYGK*
DCCGVKLEmCHOCLCDDSCKNYGK*
DCCGVKLEmCHOCLCDDSCKDYGK*
DCCGVKLγMCHPCLCDNSCKNYGK*
DCCGVKLγMCHPCLCDNSCKDYGK*
DCCGVKLγMCHPCLCDDSCKNYGK*
DCCGVKLEMCHPCLCDNSCKNYGKG*
DCCGVKLEMCHPCLCDNSCKNYGKG
DCCGVKLγmCHPCLCDNSCKNYGK*
DCCGVKLγMCHOCLCDNSCKNYGK*
DCCGVKLEmCHPCLCDNSCKNYGKG*
DCCGVKLγmCHOCLCDNSCKNYGK*
DCCGVKLγMCHPCLCDNSCKNYGKG*
RDCCGVKLEMCHPCLCDDSCKDYGK*
RDCCGVKLEmCHPCLCDNSCKNYGK*
RDCCGVKLEMCHOCLCDNSCKNYGK*
RDCCGVKLEMCHOCLCDDSCKNYGK*
RDCCGVKLEmCHPCLCDDSCKNYGK*
RDCCGVKLEmCHOCLCDNSCKNYGK*
RDCCGVKLEmCHOCLCDDSCKNYGK*
RDCCGVKLγmCHPCLCDNSCKNYGK*
DCCGVKLEMCHPCLCDNSCKNYGKGKKEY*
DCCGVKLEMCHPCLCDNSCKNYGKGKKEY
DCCGVKLEMCHPCLCDDSCKDYGKGKKEY*
DCCGVKLγMCHPCLCDNSCKNYGKGKKEY*

2890.19
2893.10
2893.10
2893.10
2893.10
2920.11
2921.09
2921.11
2933.19
3004.21
3005.20
3006.20
3020.20
3020.20
3021.20
3021.20
3021.21
3021.21
3036.20
3037.21
3038.20
3048.20
3049.21
3049.21
3061.23
3062.22
3064.22
3064.22
3077.23
3080.21
3105.24
3162.25
3176.28
3176.28
3177.27
3177.28
3192.27
3193.26
3220.28
3609.53
3610.53
3611.53
3653.54
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NAAVNDKASHLIDNVIRDCCGVKLEMCHPCLCDNSCKNYGK* 4835.18
Table 21- κ-PIVF toxiforms
D

C

C

G

V

K

L

E

M

γ

O

Annotated Sequence
DCCGVKLEMCHPCLCDNSCKK
DCCGVKLEMCHPCLCDDSCKK
DCCGVKLEmCHPCLCDNSCKK
DCCGVKLEmCHPCLCDDSCKK*
DCCGVKLEmCHPCLCDDSCKK
DCCGVKLEMCHOCLCDDSCKK
DCCGVKLγMCHPCLCDNSCKK
DCCGVKLγMCHPCLCDDSCKK
DCCGVKLγmCHPCLCDNSCKK
DCCGVKLEMCHPCLCDNSCKKS*
DCCGVKLEMCHPCLCDNSCKKS
DCCGVKLEmCHPCLCDNSCKKS*
DCCGVKLγMCHPCLCDNSCKKS*
DCCGVKLγMCHPCLCDNSCKKS
DCCGVKLEMCHPCLCDNSCKKSG*
DCCGVKLEMCHPCLCDNSCKKSG
DCCGVKLEMCHPCLCDDSCKKSG
CCGVKLEMCHPCLCDNSCKKSGK*
CCGVKLEMCHPCLCDNSCKKSGK
DCCGVKLγMCHPCLCDNSCKKSG*
DCCGVKLEMCHPCLCDNSCKKSGK*
DCCGVKLEMCHPCLCDNSCKKSGK
DCCGVKLEMCHOCLCDNSCKKSGK*
DCCGVKLEmCHPCLCDNSCKKSGK*
DCCGVKLEMCHOCLCDDSCKKSGK*
DCCGVKLEmCHPCLCDDSCKKSGK*
DCCGVKLEmCHOCLCDNSCKKSGK*
DCCGVKLEmCHOCLCDDSCKKSGK*
DCCGVKLγMCHPCLCDNSCKKSGK*
DCCGVKLγMCHPCLCDDSCKKSGK*
DCCGVKLγmCHPCLCDNSCKKSGK*
DCCGVKLγMCHOCLCDNSCKKSGK*

C

H

P

C

L

O

C

D

N
D

MH+ [Da]
2671.07
2672.05
2687.06
2687.06
2688.07
2688.07
2715.06
2716.06
2731.07
2757.12
2758.10
2773.11
2801.12
2802.11
2814.13
2815.12
2816.12
2827.20
2828.21
2858.14
2942.23
2943.24
2958.22
2958.23
2959.23
2959.23
2974.22
2975.22
2986.23
2987.23
3002.23
3002.24

Table 22- PIVH toxiforms

85

S

C

K

K

S

G

K

*

*

*

*

PIVH

R

D

C

C

G

V

V

Annotated Sequence
DCCGVVMEECHKCLCNQTC
DCCGVVMEECHKCLCNETC
DCCGVVMEECHKCLCDQTC
DCCGVVmEECHKCLCNQTC
DCCGVVMγECHKCLCNQTC*
DCCGVVMEγCHKCLCNQTC*
DCCGVVMEγCHKCLCNQTC
DCCGVVMγECHKCLCNQTC
DCCGVVMEECHKCLCNQTCK
DCCGVVMEECHKCLCDQTCK
DCCGVVMEECHKCLCNETCK
DCCGVVMγECHKCLCNQTCK*
DCCGVVMEγCHKCLCNQTCK*
DCCGVVMEγCHKCLCNQTCK
DCCGVVMγECHKCLCNQTCK
DCCGVVMEECHKCLCNQTCKK*
DCCGVVMEECHKCLCNQTCKK
DCCGVVMEECHKCLCNETCKK
DCCGVVMEECHKCLCDQTCKK
CCGVVMEECHKCLCNQTCKKK*
CCGVVMEECHKCLCNQTCKKK
DCCGVVMEγCHKCLCNQTCKK*
DCCGVVMγECHKCLCNQTCKK*
DCCGVVMγECHKCLCNQTCKK
CCGVVmγγCHKCLCNQTCKKK*
DCCGVVMEECHKCLCNQTCKKK*
DCCGVVMEECHKCLCNQTCKKK
DCCGVVmEECHKCLCNQTCKKK*
DCCGVVmEECHKCLCNETCKKK*
DCCGVVmEECHKCLCDQTCKKK*
DCCGVVmEECHKCLCDETCKKK*
DCCGVVMγECHKCLCNQTCKKK*
DCCGVVMEγCHKCLCNQTCKKK*
DCCGVVMEγCHKCLCDQTCKKK*
DCCGVVMγECHKCLCDQTCKKK*
DCCGVVMEECHKCLCNQTCKKKG*
DCCGVVMEECHKCLCNQTCKKKG
DCCGVVMEECHKCLCDETCKKKG*

M

E

E

O

γ

γ

C

H

MH+ [Da]
2459.90
2460.90
2460.90
2475.89
2502.90
2502.90
2503.91
2503.91
2587.99
2589.00
2589.00
2631.00
2631.00
2632.00
2632.00
2715.11
2716.09
2717.09
2717.09
2728.17
2729.18
2759.10
2759.10
2760.10
2832.18
2843.20
2844.20
2859.19
2860.20
2860.20
2861.18
2887.19
2887.19
2888.20
2888.20
2900.22
2901.23
2902.20
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K

C

L

C

N

Q

D

E

T

C

K

K

K

G

*

*

*

*

*

DCCGVVMEECHKCLCDQTCKKKG
DCCGVVMEECHKCLCNETCKKKG
DCCGVVmEECHKCLCNQTCKKKG*
DCCGVVmEECHKCLCDQTCKKKG
DCCGVVmEECHKCLCNETCKKKG
DCCGVVmEECHKCLCDETCKKKG*
DCCGVVMEγCHKCLCNQTCKKKG*
DCCGVVMγECHKCLCNQTCKKKG*
RDCCGVVmEECHKCLCNQTCKKK*

2902.20
2902.20
2916.22
2918.20
2918.20
2918.20
2944.22
2944.22
3015.27

Table 23- Linear-P toxiforms
LINEAR-P

F

Q

P

Z

O

S

A

Annotated Sequence
ZPSAENEEGKFRFFDKQ
ZOSAENEEGKFRFFDKQ
ZPSAENEEGKFRFFDKQQ
ZPSAENEEGKFRFFDKEQ*
FQPSAENEEGKFRFFDKQ
FQPSAENEEGKFRFFDKQQ

E

N

E

E

G

K

F

R

F

F

MH+ [Da]
2039.94
2055.94
2168.00
2168.00
2204.04
2332.10

Table 24- Ile-Contryphan-P toxiforms
Ile-Contryphan-P

A

T

S

L

G

C

V

I

W

P

W

O

Annotated Sequence
CVIWPWC
CVIWOWC
GCVIWPWC*
GCVIWPWC
GCVIWOWC
LGCVIWPWC
SLGCVIWPWC
ATSLGCVIWPWC

*

MH+ [Da]
1020.44
1036.44
1076.48
1077.46
1093.46
1190.55
1277.58
1449.66

Table 25- Contryphan-P3 toxiforms
Contryphan-P3

A

T

S

L

A

C

A

I

W
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T

K

C

C

D

K

Q

Q

E

*

Annotated Sequence
CAIWTKC
ACAIWTKC
ATSLACAIWTKC

MH+ [Da]
938.42
1009.46
1381.66

Table 26- Contryphan-P4 toxiforms
Contryphan-P4

C

Annotated Sequence
CVYWRKC

V

Y

W

R

K

C

MH+ [Da]
1071.49

Table 27- ψ-PIIIE toxiforms
R

H

P

P

O

O

C

C

L

Y

G

Annotated Sequence
OCCLYGKCRRYOGCSSASCCQ
CCLYGKCRRYOGCSSASCCQR*
HOOCCLYGKCRRYOGCSSASCC
PCCLYGKCRRYPGCSSASCCQR*
PCCLYGKCRRYOGCSSASCCQR*
OCCLYGKCRRYPGCSSASCCQR*
OCCLYGKCRRYOGCSSASCCQR*
OCCLYGKCRRYOGCSSASCCER*
OCCLYGKCRRYOGCSSASCCQR
HOOCCLYGKCRRYOGCSSASCCQ
OOCCLYGKCRRYOGCSSASCCQR*
OOCCLYGKCRRYOGCSSASCCER*
OOCCLYGKCRRYOGCSSASCCQR
HPPCCLYGKCRRYPGCSSASCCQR*
HPOCCLYGKCRRYPGCSSASCCQR*
HOPCCLYGKCRRYPGCSSASCCQR*
HPPCCLYGKCRRYOGCSSASCCQR*
HOOCCLYGKCRRYPGCSSASCCQR*
HPOCCLYGKCRRYOGCSSASCCQR*
HOOCCLYGKCRRYOGCSSASCCQR*
HOOCCLYGKCRRYOGCSSASCCER*
HOOCCLYGKCRRYOGCSSASCCQR

K

C

R

R

Y

P
O

MH+ [Da]
2659.04
2701.11
2781.09
2782.17
2798.16
2798.16
2814.16
2815.16
2815.16
2909.16
2927.20
2928.20
2928.20
3016.28
3032.27
3032.28
3032.28
3048.27
3048.27
3064.26
3065.26
3065.26
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G

C

S

S

A

S

C

C

Q

R

E

*

RHPOCCLYGKCRRYOGCSSASCCQR*
RHOOCCLYGKCRRYPGCSSASCCQR*
RHOOCCLYGKCRRYOGCSSASCCQR*
RHOOCCLYGKCRRYOGCSSASCCER*
RHOOCCLYGKCRRYOGCSSASCCQR

3204.37
3204.37
3220.38
3221.36
3221.36

Table 28- PIIIG toxiforms
PIIIG

Q

W

G

C

C

P

V

N

Z

A

C

R

S

C

H

C

C

D

Annotated Sequence
ZWGCCPVNACRSCHCC*
ZWGCCPVDACRSCHCC*

*

MH+ [Da]
2093.75
2094.74

Table 29- PIIIH toxiforms
E

I

I

L

P

A

L

G

Q

R

K

C

C

P

Z

L

T

A

C

K

L

G

S

G

C

K

C

C

E

G

V

C

F

G

O

Annotated Sequence
KCCPLTACKLGSGCKCC
CCPLTACKLGSGCKCCE
KCCPLTACKLGSGCKCCE
KCCOLTACKLGSGCKCCE
LGQRKCCPLTACKLGSGCKCCE
ZIILPALGQRKCCPLTACKLGSGCKCCE
EIILPALGQRKCCPLTACKLGSGCKCCE

MH+ [Da]
2059.87
2060.81
2188.91
2204.90
2643.17
3261.55
3279.56

Table 30- PIIII toxiforms
PIIII

C

C

Q

A

Y

C

Annotated Sequence
CCQAYCSRYHCLPCC

S

R

Y

H

C

L

P

G

L

C

C

C

MH+ [Da]
2094.75

Table 31- δ-PVIA toxiforms
E

A

C

Y

A

P
O

G

T

F

C

G

I

K

P
O
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C

S

E

F

C

L

P

*

Annotated Sequence
EACYAOGTFCGIKOGLCCSEFCLPGVC
CYAOGTFCGIKOGLCCSEFCLPGVCFG*
EASKLDKKEACYAOGTFCGIKOGLCCSEFCLPGVCFG*

MH+ [Da]
3142.29
3145.31
4244.90

Table 32- PVIB toxiforms
Q
Z

C

T

P

Y

G

G

S

C

G

V

D

S

T

C

O

C

G

R

C

N
D

Annotated Sequence

MH+ [Da]

ZCTPYGGSCGVDSTCCGRCNVPRDKC*
ZCTPYGGSCGVDSTCCGRCNVPRNKC
ZCTPYGGSCGVDSTCCGRCDVPRNKC

3033.20
3033.20
3034.20

ZCTPYGGSCGVDSTCCGRCDVPRDKC*
ZCTOYGGSCGVDSTCCGRCNVPRDKC*
ZCTOYGGSCGVDSTCCGRCNVPRNKC
ZCTOYGGSCGVDSTCCGRCDVPRDKC*
ZCTOYGGSCGVDSTCCGRCDVPRNKC
CTPYGGSCGVDSTCCGRCNVPRNKCE

3034.20
3049.19
3049.19
3050.19
3050.19
3051.21

CTOYGGSCGVDSTCCGRCNVPRNKCE
CTOYGGSCGVDSTCCGRCNVPRDKCE*
CTOYGGSCGVDSTCCGRCNVORNKCE
CTOYGGSCGVDSTCCGRCNVORDKCE*
CTOYGGSCGVDSTCCGRCDVORNKCE*
ZCTPYGGSCGVDSTCCGRCNVPRDKCE*

3067.20
3067.20
3083.20
3083.20
3083.20
3162.24

ZCTPYGGSCGVDSTCCGRCDVPRNKCE*
ZCTPYGGSCGVDSTCCGRCNVPRNKCE
ZCTPYGGSCGVDSTCCGRCDVPRDKCE*
ZCTPYGGSCGVDSTCCGRCDVPRNKCE
ZCTPYGGSCGVDSTCCGRCNVPRDKCE
ZCTPYGGSCGVDSTCCGRCDVPRDKCE

3162.24
3162.25
3163.24
3163.24
3163.24
3164.23

ZCTOYGGSCGVDSTCCGRCNVPRNKCE
ZCTOYGGSCGVDSTCCGRCNVPRDKCE*
ZCTPYGGSCGVDSTCCGRCNVORDKCE*
ZCTPYGGSCGVDSTCCGRCNVORNKCE
ZCTPYGGSCGVDSTCCGRCDVORNKCE*
ZCTPYGGSCGVDSTCCGRCNVORDKCE

3178.23
3178.23
3178.23
3178.23
3178.23
3179.23

ZCTPYGGSCGVDSTCCGRCDVORNKCE
ZCTPYGGSCGVDSTCCGRCDVORDKCE*
ZCTOYGGSCGVDSTCCGRCDVPRNKCE
ZCTOYGGSCGVDSTCCGRCDVPRDKCE*

3179.23
3179.23
3179.24
3179.24
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V

P
O

R

N
D

K

C

E

L

γ
*

*

ZCTOYGGSCGVDSTCCGRCNVPRDKCE
QCTPYGGSCGVDSTCCGRCNVPRNKCE
ZCTOYGGSCGVDSTCCGRCDVPRDKCE
QCTPYGGSCGVDSTCCGRCNVPRDKCE
ZCTPYGGSCGVDSTCCGRCDVORDKCE

3179.24
3179.24
3180.22
3180.22
3180.22

QCTPYGGSCGVDSTCCGRCDVPRDKCE*
QCTPYGGSCGVDSTCCGRCDVPRNKCE
ZCTPYGGSCGVDSTCCGRCNVPRNKCE
ZCTPYGGSCGVDSTCCGRCNVPRDKCE*
QCTPYGGSCGVDSTCCGRCDVPRDKCE
ZCTOYGGSCGVDSTCCGRCNVORNKCE*

3180.24
3180.24
3180.24
3180.24
3181.21
3193.25

ZCTOYGGSCGVDSTCCGRCNVORNKCE
ZCTOYGGSCGVDSTCCGRCNVORDKCE*
ZCTOYGGSCGVDSTCCGRCDVORNKCE*
ZCTOYGGSCGVDSTCCGRCNVORDKCE
ZCTOYGGSCGVDSTCCGRCDVORNKCE
QCTPYGGSCGVDSTCCGRCNVORDKCE*

3194.23
3194.23
3194.24
3195.22
3195.23
3195.23

QCTPYGGSCGVDSTCCGRCNVORNKCE
ZCTOYGGSCGVDSTCCGRCNVPRNKCγ*
ZCTPYGGSCGVDSTCCGRCNVORNKCγ
ZCTOYGGSCGVDSTCCGRCDVPRNKCγ
ZCTPYGGSCGVDSTCCGRCNVPRDKCEL
ZCTPYGGSCGVDSTCCGRCDVPRNKCEL

3195.23
3222.22
3222.25
3223.22
3276.28
3276.28

ZCTPYGGSCGVDSTCCGRCDVPRDKCEL*
ZCTPYGGSCGVDSTCCGRCDVPRDKCEL
ZCTOYGGSCGVDSTCCGRCNVPRDKCEL
ZCTOYGGSCGVDSTCCGRCDVPRDKCEL*
ZCTOYGGSCGVDSTCCGRCDVPRNKCEL
ZCTPYGGSCGVDSTCCGRCDVORNKCEL

3276.28
3277.29
3292.27
3292.27
3292.27
3292.27

ZCTPYGGSCGVDSTCCGRCDVORDKCEL*
ZCTOYGGSCGVDSTCCGRCDVPRDKCEL
ZCTOYGGSCGVDSTCCGRCNVORDKCEL
ZCTOYGGSCGVDSTCCGRCDVORNKCEL
ZCTOYGGSCGVDSTCCGRCDVORDKCEL
ZCTPYGGSCGVDSTCCGRCNVORNKCγL

3292.27
3293.27
3308.27
3308.27
3309.27
3335.31

ZCTPYGGSCGVDSTCCGRCNVORDKCγL*
ZCTPYGGSCGVDSTCCGRCDVORNKCγL*
ZCTOYGGSCGVDSTCCGRCDVPRDKCγL

3335.31
3335.31
3337.27

Table 33- PVIC sites of modification **There were no spectral matches to the full PVIC
mature peptide. Sites of modification were determined by matches to peptide fragments
E

A

C

Y

A

P

G

T

F

C

G

I

K

P

G

91

L

C

C

S

A

L

C

L

P

A

V

C

I

D

Z

O

O

*

*

Table 34- PVID toxiforms
S

N

R

P

D

C

K

K

S

G

R

K C

F

O

P H

Q

O

E

K D

C

C

G

R

A C

I

I T

I

C P
*

Annotated Sequence

MH+ [Da]

SNROCKKSGRKCFOHQKDCCGRACIITICP
SNROCKKSGRKCFOHEKDCCGRACIITICP*
SDROCKKSGRKCFOHQKDCCGRACIITICP*

3723.74
3723.74
3723.74

Table 35- PVIE toxiforms
V

G

E

F

R

G

C

A

H

I

N

Q

D

E

A

C

N

P

P

Q

D

O

O

E

Annotated Sequence

C

C

R

G

Y

T

C

Q

S

S

Y

I

P

S

C

O

Q

L

E

*

MH+ [Da]

GCAHINQACNOOQCCRGYTCQSSYIOSCQL
GCAHINQACNOOQCCRGYTCQSSYIOSCEL*

3635.47
3635.47

VGEFRGCAHINQACNPPQCCRGYTCQSSYIOSCQL
VGEFRGCAHINQACNPPQCCRGYTCQSSYIOSCEL*
VGEFRGCAHINQACNPOQCCRGYTCQSSYIOSCQL
VGEFRGCAHINQACNPOQCCRGYTCQSSYIOSCEL*
VGEFRGCAHINQACNPOECCRGYTCQSSYIOSCQL*
VGEFRGCAHINQACDPOQCCRGYTCQSSYIOSCQL*

4191.78
4191.78
4207.77
4207.77
4207.77
4207.77

VGEFRGCAHINQACNOOQCCRGYTCQSSYIPSCQL
VGEFRGCAHINQACNOOQCCRGYTCQSSYIPSCEL*
VGEFRGCAHINQACNOOQCCRGYTCQSSYIOSCQL
VGEFRGCAHINQACNOOQCCRGYTCQSSYIOSCEL*
VGEFRGCAHINEACNOOQCCRGYTCQSSYIOSCQL*
VGEFRGCAHINQACDOOQCCRGYTCQSSYIOSCQL*

4207.77
4207.77
4223.76
4223.76
4223.77
4223.77

VGEFRGCAHIDQACNOOQCCRGYTCQSSYIOSCQL*
VGEFRGCAHINQACNOOECCRGYTCQSSYIOSCQL*

4223.77
4223.77

Table 36- PVIF toxiforms
A

T

S

N
D

R

P

C

K

K

T

G

R

K

O

C

F

P
O

H

Q

K

E

Annotated Sequence

MH+ [Da]

ATSNROCKKTGRKCFOHEKDCCGRACIITICP*

3909.83

92

D

C

C

G

R

A

C

I

I

T

I

C

P
*

ATSDROCKKTGRKCFOHQKDCCGRACIITICP*
ATSNROCKKTGRKCFOHQKDCCGRACIITICP

3909.83
3909.83

Table 37- PVIG toxiforms
S T T K G A T S N R P C K I P G R K C F P H Q K D
D

O

O

O

E

C C G R A C I I T I C P
*

Annotated Sequence

MH+ [Da]

GATSNROCKIOGRKCFPHqKDCCGRACIITICP*
GATSNRPCKIOGRKCFOHqKDCCGRACIITICP*
GATSNROCKIOGRKCFPHQKDCCGRACIITICP
GATSNRPCKIOGRKCFOHQKDCCGRACIITICP
GATSNROCKIOGRKCFPHqKDCCGRACIITICP

3947.85
3947.85
3947.85
3947.85
3948.84

GATSNRPCKIOGRKCFOHqKDCCGRACIITICP
GATSDROCKIOGRKCFOHQKDCCGRACIITICP*
GATSNROCKIOGRKCFOHqKDCCGRACIITICP*
GATSNROCKIOGRKCFOHQKDCCGRACIITICP
GATSDROCKIOGRKCFOHqKDCCGRACIITICP
STTKGATSNROCKIOGRKCFPHqKDCCGRACIITICP*

3948.84
3963.83
3963.85
3963.85
3965.82
4365.07

STTKGATSDROCKIOGRKCFPHQKDCCGRACIITICP*
STTKGATSDRPCKIOGRKCFOHQKDCCGRACIITICP*
STTKGATSNROCKIOGRKCFPHQKDCCGRACIITICP
STTKGATSNROCKIOGRKCFOHqKDCCGRACIITICP*
STTKGATSDROCKIOGRKCFOHQKDCCGRACIITICP*

4365.07
4365.07
4365.07
4381.06
4381.07

Table 38- κ-PVIIA toxiforms
C

R

I

P

N

Q

O

D

E

K

C

F

Q

H

L

D

D

E

C

C

S

R

K

C

N
D

Annotated Sequence

MH+ [Da]

CRIPNQKCFQHLDDCCSRKCNRFNKCV
CRIPNQKCFQHLDDCCSRKCDRFNKCV
CRIPNQKCFQHLDDCCSRKCNRFDKCV
CRIPNQKCFQHLDDCCSRKCDRFDKCV*
CRIPNQKCFEHLDDCCSRKCNRFNKCV

3600.58
3601.57
3601.57
3601.57
3601.58
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R

F

N
D

K

C

V
*

CRIPDQKCFQHLDDCCSRKCDRFNKCV
CRIONQKCFQHLDDCCSRKCDRFNKCV*
CRIONQKCFQHLDDCCSRKCNRFDKCV*
CRIONQKCFQHLDDCCSRKCNRFNKCV
CRIODQKCFQHLDDCCSRKCDRFNKCV*

3602.57
3616.60
3616.60
3616.60
3617.59

CRIODQKCFQHLDDCCSRKCNRFNKCV
CRIONQKCFQHLDDCCSRKCDRFDKCV*
CRIONQKCFQHLDDCCSRKCDRFNKCV
CRIONQKCFQHLDDCCSRKCNRFDKCV
CRIONEKCFQHLDDCCSRKCNRFNKCV
CRIONQKCFEHLDDCCSRKCNRFNKCV

3617.59
3617.60
3617.60
3617.60
3617.60
3617.61

CRIONEKCFQHLDDCCSRKCNRFDKCV*
CRIONQKCFQHLDDCCSRKCDRFDKCV

3617.61
3618.59

Table 39- Contryphan-P toxiforms
Contryphan-P

G

C

P

W

D

P

W

C

O

*

Annotated Sequence

Thγo. MH+ [Da]

GCOWDPWC*

1092.403

Table 40- PIIA toxiforms
PIIA

C

C

C

I

R

S

D

G

P

K

Annotated Sequence

MH+ [Da]

CCIRSDGPKCSRKCLSSFFC
CCCIRSDGPKCSRKCLSSFFC

2525.10
2685.13

C

S

R

K

C

L

S

S

F

F

C

C

I

C

G

G

L

S

Table 41- PVIIIA toxiforms
G

C

S

G

S

P

C

F

K

O

G

Y

G

G

S

R

C

N

K

T

C

R

D

G

C

K

C

D

E
γ

T

C

R

94

E

N
D

C

W

Annotated Sequence

MH+ [Da]

CSGSOCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE

4857.92

CSGSOCFKNKTCRDγCICGGLSNCWCGYGGSRGCKCTCRE
CSGSPCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE
CSGSPCFKDKTCRDECICGGLSNCWCGYGGSRGCKCTCRE
CSGSPCFKNKTCRDECICGGLSDCWCGYGGSRGCKCTCRE
CSGSOCFKNKTCRDECICGGLSDCWCGYGGSRGCKCTCRE
CSGSOCFKDKTCRDECICGGLSNCWCGYGGSRGCKCTCRE

4901.90
4841.91
4842.92
4842.89
4858.90
4858.90

CSGSOCFKDKTCRDECICGGLSDCWCGYGGSRGCKCTCRE
CSGSOCFKDKTCRDγCICGGLSNCWCGYGGSRGCKCTCRE
CSGSOCFKNKTCRDγCICGGLSDCWCGYGGSRGCKCTCRE
CSGSOCFKDKTCRDγCICGGLSDCWCGYGGSRGCKCTCRE
CSGSPCFKNKTCRDγCICGGLSNCWCGYGGSRGCKCTCRE
CSGSPCFKDKTCRDECICGGLSDCWCGYGGSRGCKCTCRE

4859.92
4902.93
4902.93
4903.91
4885.87
4843.91

GCSGSOCFKNKTCRDECICGGLSDCWCGYGGSRGCKCTC
GCSGSOCFKDKTCRDECICGGLSNCWCGYGGSRGCKCTC
GCSGSOCFKDKTCRDγCICGGLSDCWCGYGGSRGCKCTC
GCSGSOCFKDKTCRDECICGGLSDCWCGYGGSRGCKCTC
GCSGSPCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE
GCSGSPCFKDKTCRDECICGGLSDCWCGYGGSRGCKCTCRE

4630.80
4630.78
4675.78
4631.79
4898.92
4900.92

GCSGSOCFKNKTCRDECICGGLSNCWCGYGGSRGCKCTCRE
GCSGSOCFKNKTCRDECICGGLSDCWCGYGGSRGCKCTCRE
GCSGSOCFKDKTCRDECICGGLSNCWCGYGGSRGCKCTCRE
GCSGSPCFKNKTCRDECICGGLSDCWCGYGGSRGCKCTCRE
GCSGSOCFKDKTCRDECICGGLSDCWCGYGGSRGCKCTCRE
GCSGSPCFKNKTCRDγCICGGLSNCWCGYGGSRGCKCTCRE

4914.93
4915.94
4915.93
4899.93
4916.93
4942.91

GCSGSOCFKDKTCRDγCICGGLSNCWCGYGGSRGCKCTCRE
GCSGSOCFKNKTCRDγCICGGLSDCWCGYGGSRGCKCTCRE
GCSGSOCFKNKTCRDγCICGGLSNCWCGYGGSRGCKCTCRE
GCSGSPCFKDKTCRDECICGGLSNCWCGYGGSRGCKCTCRE
GCSGSOCFKDKTCRDγCICGGLSDCWCGYGGSRGCKCTCRE
GCSGSPCFKDKTCRDγCICGGLSNCWCGYGGSRGCKCTCRE

4959.92
4959.91
4958.93
4899.93
4960.91
4943.91

GCSGSPCFKDKTCRDγCICGGLSDCWCGYGGSRGCKCTCRE
GCSGSPCFKNKTCRDγCICGGLSDCWCGYGGSRGCKCTCRE

4944.92
4943.92

Table 42- PVA toxiforms
PVA

G

C

C

P

K

Q

M

R

C

C

T

L
*

95

Annotated Sequence

MH+ [Da]

GCCPKQMRCCTL
GCCPKQMRCCTL*

1570.64
1569.66

Table 43- PVB toxiforms
PVB

R

D

C

C

P

E

K

O

M

W

C

C

O

Annotated Sequence

P

L

O

*

MH+ [Da]

DCCPEKMWCCP
DCCOEKmWCCP

1542.53
1574.52

DCCOEKMWCCP
DCCPEKmWCCP
DCCOEKMWCCPL*
DCCPEKmWCCPL*
DCCPEKMWCCPL*
DCCOEKMWCCOL*

1558.52
1558.52
1670.62
1670.62
1654.63
1686.62

DCCOEKmWCCPL*
RDCCPEKMWCCP
RDCCPEKMWCCPL*

1686.62
1698.63
1810.73

Table 44- p21b sites of modification on the two identified peptides. **There were no
spectral matches to the full PVIC mature peptide. Sites of modification were determined
by matches to peptide fragments
A

F E L L P S Q D R S C C I R K T L E C L E N Y P G Q E S Q R A H Y
O
E
O
E
*
S

B

I

N

A

Q

N

N

V

R

P
O

A

H

D
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T

C

I

N

R

L

C

F

D

P

G

F

APPENDIX B: Chromatograms (TIC) of injected venom samples from
C. purpurascens specimens.

Figure 26- Total ion chromatogram from venom sample of specimen 1

Figure 27- Total ion chromatogram from venom sample of specimen 2

97

Figure 28- Total ion chromatogram from venom sample of specimen 3

Figure 29- Total ion chromatogram from venom sample of specimen 4
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Figure 30- Total ion chromatogram from venom sample of specimen 5

Figure 31- Total ion chromatogram from venom sample of specimen 6
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Figure 32- Total ion chromatogram from venom sample of specimen 7

Figure 33- Total ion chromatogram from venom sample of specimen 8
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Figure 34- Total ion chromatogram from venom sample of specimen 9

Figure 35- Total ion chromatogram from venom sample of specimen 10
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Figure 36- Total ion chromatogram from venom sample of specimen 11

Figure 37- Total ion chromatogram from venom sample of specimen 12
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Figure 38- Total ion chromatogram from venom sample of specimen 13

Figure 39- Total ion chromatogram from venom sample of specimen 14
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Figure 40- Total ion chromatogram from venom sample of specimen 15

Figure 41- Total ion chromatogram from venom sample of specimen 1
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Figure 42- Total ion chromatogram from venom sample of specimen 17

Figure 43- Total ion chromatogram from venom sample of specimen 18
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Figure 44- Total ion chromatogram from venom sample of specimen 19

Figure 45- Total ion chromatogram from venom sample of specimen 20
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Figure 46- Total ion chromatogram from venom sample of specimen 21

Figure 47- Total ion chromatogram from venom sample of specimen 22
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Figure 48- Total ion chromatogram from venom sample of specimen 23

Figure 49- Total ion chromatogram from venom sample of specimen 24
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Figure 50- Total ion chromatogram from venom sample of specimen 25

Figure 51- Total ion chromatogram from venom sample of specimen 26
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Figure 52- Total ion chromatogram from venom sample of specimen 27
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APPENDIX C: Features of the New Conopeptides in Conus purpurascens
Here we describe the main features of newly discovered conopeptides in the injected
venom of C. purpurascens. We include the sequence of the precursor proteins from the
transcriptome and highlight the corresponding signal and mature sequences. We also
show the annotated MS/MS spectra. When possible, we compare the novel C.
purpurascens sequences to known conopeptides, which can confer putative structural and
functional characteristics to these newly described peptides.
Linear
Linear-P belongs to the B2 Superfamily. This family of linear peptides is expressed in
other Conus species based on sequences deposited in NCBI. A similar sequence, differing
in a single residue, is expressed by C. ermineus (Sequence ID: AXL95472) [197], a close
relative to C. purpurascens. This is the first evidence of these B2 linear peptides in
injected venom.

Figure 53- Supplementary information for Linear-P. 1) full transcript with annotated
signal sequence and mature peptide regions and 2) annotated MSMS spectra
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One disulfide (C-C)
Ile-contryphan-P belongs to the M superfamily. Ile-contryphan-P exhibits sequence
homology to previously described leu-contryphan-P, except for a switch from L5 to W5. In
general, contryphans are characterized by a conserved motif containing D-tryptophan or
leucine and a single disulfide bond. Contryphans typically classify as part of the O2
superfamily based on their signal sequence, however Ile-contryphan-P does not follow
this trend. The molecular target of contryphans remain unclear. Here, Ile-contryphan-P
was identified in 25 of the 27 venom samples, suggesting it has an important function that
needs to be discerned.

Figure 54- Supplementary information for Ile-Contryphan-P. 1) full transcript with
annotated signal sequence and mature peptide regions and 2) annotated MSMS spectra

Contryphan-P3 belongs to the M superfamily. Based on precursor analysis, these
peptides form a new group of one disulfide peptides within the M superfamily [98].
Contryphan-P3 is also expressed by C. ermineus (Sequence ID: AXL95407) [197], but
this is the first instance in venom.
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Figure 54- Supplementary information for contryphan-P 1) full transcript with
annotated signal sequence and mature peptide regions and 2) annotated MSMS spectra

Contryphan-P4 is not expressed in the venom duct, it was first discovered by de novo
sequencing using PEAKS software (Unpublished data from our lab). Like Contryphan P3,
the same sequence is found in C. ermineus venom duct transcriptome and belongs to the
M superfamily (Sequence ID: AXL95569). Contryphan-P3 and P4 have different
expression patterns and cluster into separate cabals.

Figure 54- Supplementary information for Contryphan-P3 1) mature peptide sequence
as determined by de novo sequencing and 2) annotated MSMS spectra
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Framework I (CC-C-C)
PID belongs to superfamily A. The sequence of PID has been previously reported as a
nucleic acid sequence from C. ermineus, E1.1 precursor (P03002, Conoserver). Here we
provide the first evidence for the mature peptide in milked venom from C. purpurascens.
The mature peptide exhibits homology to α-PIA (C. purpurascens) and to α-GID (C.
geographus, P60274), suggesting PID will inhibit the nAChR [161, 198].

Figure 55- Supplementary information for PID 1) full transcript with annotated signal
sequence and mature peptide regions, 2) annotated MSMS spectra and 3) sequence
alignment with α-PID and α-GID.

PIE belongs to superfamily A. Homology to α-conotoxin precursor Bt1.8 from C. betulinus
(Sequence ID: A0A068B6Q6) and characterized α-GIC (Sequence ID: Q86RB2) that
inhibits α3β2 receptors [199]. Interestingly, MS/MS data from this study identified PIE with
an extended N-terminal tail lacked by characterized α-conotoxins.
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Figure 56- Supplementary information for PIE 1) full transcript with annotated signal
sequence and mature peptide regions, 2) annotated MSMS spectra, and 3) sequence
alignment with α-GIC

PIF is a new framework I conotoxin that was first sequenced de novo using PEAKS
(Unpublished data). Because it was sequenced de novo, the superfamily is unable to be
assigned. The mature peptide shows homology to EIIA from C. ermineus (Sequence ID:
D4HRK4) which inhibits muscle subtype nAChRs [200]. PIF is also similar to α-PIB, a
muscle subtype-selective conotoxin from C. purpurascens [201].
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Figure 57- Supplementary information for PIF 1) mature peptide sequence as
determined by de novo sequencing, 2) annotated MSMS spectra, and 3) sequence
alignment with α-PIF and α-EIIA

PIG is a framework I conotoxin that was sequenced de novo using PEAKS software
(Unpublished data). We lack signal sequence information, however the mature peptide
sequence shows high homology (82%) to α-PIA that inhibits α6 nAChRs [161].
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Figure 58- Supplementary information for PIG 1) mature peptide sequence as
determined by de novo sequencing, 2) annotated MSMS spectra, and 3) alignment with
α-PIA
Framework II (CCC-C-C-C)
PIIA exhibits cysteine framework II and belongs to the O3 Superfamily. A very similar
sequence is found in the C. ermineus venom duct transcriptome (Sequence ID:
AXL95373) [197]. There are no similar characterized conotoxins from which we can infer
activity. It is important to note that there is an extra cystine pair upstream from the identified
N-terminus, and it is possible that the mature peptide identified through our approaches
was in fact a truncated version. If this extra cysteine pair is part of the mature peptide, it
would form a novel four-disulfide peptide with a new cysteine framework (C-C-CCC-C-CC).
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Figure 59- Supplementary information for PIIA 1) full transcript with annotated signal
sequence and mature peptide regions and 2) annotated MSMS spectra

Framework III (CC-C-C-CC)
PIIIG belongs to the M superfamily that clusters with the motor cabal. It is an M1 mini-M
with loops sizes 4/2/1 according to the number of residues between cysteine residues
[125]. The mature peptide has very little sequence homology to other mini-Ms. The
pharmacology of the mini-Ms remains unknown, despite their prevalence across Conus
species [124].

Figure 60- Supplementary information for PIIIG 1) full transcript with annotated mature
peptide region and 2) annotated MSMS spectra

PIIIH is an M superfamily conotoxin that clusters with the motor cabal. It is an M1 mini-M
with loop sizes 4/5/1. PIIIH clusters with motor cabal toxins. It exhibits sequence homology
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to a peptide expressed in the venom duct of fish-hunting cone snail C. magus (Sequence
ID: QFQ61044), however there is no evidence of this peptide in the injected venom [202].

Figure 61- Supplementary information for PIIIH 1) full transcript with annotated signal
sequence and mature peptide regions and 2) annotated MSMS spectra

PIIII is a mini-M (M2) from the M Superfamily. It is the only one of the 3 identified venom
mini-Ms that clustered with lightning-strike cabal peptides. Similar transcripts are found in
Turriconus species (ATF27414, ATF27651) [203], and in C. regius (P85021) [124]. These
are all worm-hunting species, supporting previous evidence that C. purpurascens may
employ a mixed-mode feeding strategy (Unpublished data).
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Figure 62- Supplementary information for PIIII 1) full transcript with annotated signal
sequence and mature peptide regions and 2) annotated MSMS spectra

Framework IV (CC-C-C-C)
PIVH belongs to the A superfamily. Its expression in the milked venom clusters closely
with κ-PIVF and other lightning strike cabal toxins. PIVH shares ~60% homology with κPIVE and κ-PIVF, strongly indicating it also targets the potassium channel [204].

120

Figure 63- Supplementary information for PIVH 1) full transcript with annotated signal
sequence and mature peptide regions 2) annotated MSMS spectra, and 3) alignment with
κ-PIVF and κ-PIVE

Framework V (CC-CC)
PVB is a T Superfamily conotoxin expressed in both transcriptomes. Its expression in the
milked venom clustered closely with other motor cabal peptides. PVB is the second T
Superfamily peptide identified from C. purpurascens venom but shows limited sequence
homology to PVA aside from the conserved cysteine framework. The same sequence is
found in the transcriptome of C. ermineus (Sequence ID: AXL95476) [197]. The
pharmacology of T superfamily conotoxins is not well defined, however, two framework V
conotoxins from the T Superfamily are known to target the somatostatin-3 receptor [205].
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Figure 64- Supplementary information for PVB 1) full transcript with annotated signal
sequence and mature peptide regions and 2) annotated MSMS spectra

Framework VI/VII (C-C-CC-C-C)
PVIB is an O1 Superfamily conotoxin. PVIB was identified in 21 of the 27 venom samples
suggesting it plays an important role in prey capture. It falls within cluster 1 (lightning-strike
cabal) and is expressed in the venom of all 7 specimens that form this cluster. PVIB has
high homology to a sequence from the venom duct transcriptome of C. ermineus
(Sequence ID: AXL95467) [197].

Figure 64- Supplementary information for PVIB 1) full transcript with annotated signal
sequence and mature peptide regions and 2) annotated MSMS spectra

PVIC belongs to the O1 Superfamily. It shows high homology (85%) to δ-PVIA, and the
two share similar patterns of expression in the venom. Its sequence is also similar to δ-
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EVIB (Sequence ID: P69752). For this reason, it is likely PVIC will also target sodium
channels [113] as part of the lightning-strike cabal.

Figure 65- Supplementary information for PVIC A) full transcript with annotated signal
sequence and mature peptide regions and B) alignment with δ-PVIA and δ-EVIB

PVID belongs to the O1 Superfamily. It was previously reported as a nucleic acid
sequence, P2b (Sequence ID: AAQ05866) [1], but this is the first time reported in the
venom. It clusters within the lightning strike cabal. It closely resembles C. purpurascens
nucleic acid sequence p2a (Sequence ID: AAQ05865), and new peptides PVIF (p2c,
AAQ05867), and PVIG [1]. It does not share homology to any peptides with known activity.
It does not share significant homology to any peptides with known activity, however it has
the same cysteine framework and minimal homology to κ-PVIIA.
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Figure 66- Supplementary information for PVID 1) full transcript with annotated signal
sequence and mature peptide regions and 2) annotated MSMS spectra

PVIE belongs to the O1 Superfamily. The mature peptide has little sequence homology to
any characterized conotoxin but has high homology to a nucleic acid sequence from C.
ermineus (Sequence ID: AXL95668) [197]. Interestingly, it is the only framework VI/ O1
Superfamily toxin that is expressed within cluster 2 (motor cabal).

Figure 67- Supplementary information for PVIE 1) full transcript with annotated signal
sequence and mature peptide regions and 2) annotated MSMS spectra
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PVIF belongs to the O1 Superfamily. It was previously reported as a nucleic acid
sequence, P2c (Sequence ID: AAQ05867) [1], but this is the first time reported in the
venom. PVIF was only identified in the venom of one specimen. It closely resembles C.
purpurascens nucleic acid sequences p2a (Sequence ID: AAQ05865), PVID (p2b,
AAQ05866) and PVIG [1]. It clusters within the lightning strike cabal. It does not share
significant homology to any peptides with known activity but shares minimal homology
with κ-PVIIA.

Figure 68- Supplementary information for PVIF 1) full transcript with an annotated
signal sequence and mature peptide regions and 2) annotated MSMS spectra

PVIG is a new O1 Superfamily conotoxin. It closely resembles C. purpurascens nucleic
acid sequences p2a (Sequence ID: AAQ05865), PVID (p2b, AAQ05866) and PVIF (p2c,
AAQ05867) [1]. PVIG clustered with the lightning-strike cabal, although was only identified
in one specimen. It does not share significant homology to any peptides with known
activity, however, it has the same cysteine framework and minimal homology to κ-PVIIA.
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Figure 69- Supplementary information for PVIG 1) full transcript with annotated signal
sequence and mature peptide regions, 2) annotated MSMS spectra, and 3) sequence
alignment with PVIF, and PVID, and κ-PVIIA.

Framework VIII (C-C-C-CXC-CXC-CXCXC)
PVIIIA belongs to the S Superfamily of conotoxins and contains 5 disulfide bonds. It was
identified in 25 of the 27 venom samples, and therefore likely has an important role in the
venom that has yet to be revealed. It clusters closely with ψ-PIIIE and α-PIVA and is a
major component of the motor cabal. There are few framework VIII conotoxins with known
bioactivity; two target the nAChR (α-GVIIIB, α-RVIIA) [206, 207] and one targets the
serotonin receptor (σ-GVIIIA) [208]. However, PVIIIA does not display high sequence
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homology to any of these characterized toxins, aside from a conserved cysteine
framework.

Figure 70- Supplementary information for PVIIIA 1) full transcript with annotated signal
sequence and mature peptide regions, 2) annotated MSMS spectra, and 3) sequence
alignment with σ-GVIIIA, α-GVIIIB, and α-RVIIIA

Framework XXI (CC-C-C-C-CC-C-C-C)
p21b was expressed in transcriptome B and its precursor sequence classifies it as part of
the con-ikot-ikot family. It shows 91% identity to P21a, a previously described 10 cysteine,
5-disulfide conotoxin [127]. P21a was not expressed in either transcriptome and was not
detected in the milked venom. However, P21b was identified in 10 of the 27 venom
samples. It clusters closely to PVB and PIIIH, both newly described here. A con-ikot-ikot
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isolated from C. striatus targets the AMPA receptor and is presumed to contribute to the
lightning strike cabal [209]. In this study, P21b expression in the venom clusters with motor
cabal toxins, suggesting an alternative molecular target for the con-ikot-ikot family of
knottin peptides.

Figure 71- Supplementary information for p21b 1) full transcript with annotated signal
sequence and mature peptide regions and 2) sequence alignment with p21a and con-ikotikot S
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APPENDIX D: Alignment of gastropod insulin superfamily proteins.
A0A0B5ADV0|Con-Ins
A0A0B5A8P4|Con-Ins
A0A0B5AC86|Con-Ins
A0A0B5A7P2|Con-Ins
A0A0B5A8Q2|Con-Ins
A0A0B5AC95|Con-Ins
A0A0B5ADU4|Con-Ins
A0A0B5ABD5|Con-Ins
A0A0B5AC90|Con-Ins
A0A0B5ABD9|Con-Ins
A0A0B5ADT3|Con-Ins
A0A0B5ABE4|Con-Ins
A0A0B5ABE6|Con-Ins
A0A0B5AC98|Con-Ins
A0A0B5A7N5|Con-Ins
A0A0B5A7N1|Con-Ins
A0A0B5ADT9|Con-Ins
A0A0B5A8Q6|Con-Ins
A0A0B5A7N8|Con-Ins
A0A0F7YYV0|ILP-1
P91797|MIP-7
Q9NDE7|MIP-1
P80090|MIP-3
P07223|MIP-1
P25289|MIP-2
P31241|MIP-5
A0A0B5A7M7|Con-Ins
A0A0B5A8P8|Con-Ins

Me1
G3
G3b
G1C
G1b
G1a
T1
T3
T2
G2
G2b
Q1b
Q1
F1
F2C
F2b
F2
M1
Tx1

-------MATSSCFLLVTLG--LLLHVQQ-AFLHE-HTCSPSEP---AAPGGICGSNLAELHSFLCEKELEDY-------------MTTSFYFLLVALG--LLLYVCQSSFGNQ-HTRNSDTP------KHRCGSELADQYVQLCH------GK-----------MTTSFYFLLVALG--LLLYVCQSSFGNQ-HTRNSDTP------KHRCGSELADQYVQLCH------GK-----------MTTSFYFLLMALG--LLLYVCQSSFGNQ-HTRTFDTP------KHRCGSEITNSYMDLCY------RK-----------MTTSFYFLLMALG--LLLYVCQSSFGNQ-HTRTFDTP------KHRCGSEITNSYMDLCY------RK-----------MTTSSYFLLMALG--LLLYVCQSSFGNQ-HTRTFDTP------KHRCGSEITNSYMDLCY------RK-----------MTTSFYFLLMALG--LLLYVCQSSFGNQ-HTRNSDTP------KYRCGSEIPNSYIDLCF------RK-----------MTTSFYFLLMALG--LLLYVCQSSFGNQ-HTRNSDTP------KYRCGSDIPNSYMDLCF------RK-----------MTTSFYFLLMALG--LLLYVCQSSFGNQ-HTRNSDTP------KYRCGSDIPNSYMDLCF------RK-----------MTTSSYFLLVALG--LLLYVRQSFSTHE-HTCQLDDP---AHPQGKCGSDLVNYHEEKCEEEEARRGG-----------MTTSSYFLLVALG--LLLYVRQSFSTHE-HTCQLDDP---AHPQGKCGSDLVNYHEEKCEEEEARRGG-----------MTTSSYFLLVALG--LLLYLCQSSFGTE-HTCEPGAS---PHPQGKCGPELAEFHETMCEVEESLQGG-----------MTTSSYFLLVALG--LLLYLCQSSFGTE-HTCEPGAS---PHPQGKCRPELAEFHETMCEVEESLQGG-----------MTTSSYFLLVTLG--LLLYVCRSSFGTE-HTCESDAS---PHPQGVCGSPLAEAVEAACELEEYLQGG-----------MTTSSYFLLVALG--LLLYVCRSSFGSE-HTCESDAS---PHPQGVCGSPLAEAVEAACELEQSLQGG-----------MTTSSYFLLVALG--LLLYVCRSSFGSE-HTCESDAS---PHPQGVCGSPLAEAVEAACELEESLQGG-----------MTTSSYFLLVALG--LLLYVCRSSFGSE-HTCESDAS---PHPQGVCGSPLAEAVEAACELEESLQGG-----------MTTSSYFLLVALG--LLLYVCQSSFGGE-HVCGSNQP---NHPNGKCGSKMADYLEEQCEEEEAAHGG-----------MTTSSYFLLVALG--LLLYVFQSSFGGE-HVCWLGDP---NHPQGICGPQVADIVEIRCEEKEAEQGG-----------MTTSSYFLLVALG--LLLYVCQSSFGGE-HVCWLDDP---NHPEGICGPQVSDIVEIRCEEKEAEQGG---------MNASVESCLTFTFVL--VALCVGLTIG-QQVNTCTMFSR---QHPRGLCGNRLARAHANLCFLLRNTYPDIFPRK
MSKFLLQSHSANACLLTLLLT-LASNLDISLANFE-HSCNGYMR---PHPRGLCGEDLHVIISNLCSSLGGNR------MASV--HLTLTKAFMVTVFLT-LLLNVSITRGTTQ-HTCSILSR---PHPRGLCGSTLANMVQWLCSTYTTSSKVK--RMAGV--RLVFTKAFMVTVLLT-LLLNIGVKPAEGQFSACNINDR---PHRRGVCGSALADLVDFACSSSNQPAMVK---MVGV--RLVFTNAFVVTVLLT-LLLDVVVKPAEGQ-SSCSLSSR---PHPRGICGSNLAGFRAFICSNQNSPSMVK--RMAGV--RLVFTKAFMVTVLLT-LLLNIGVKPAEGQFSACSFSSR---PHPRGICGSDLADLRAFICSRRNQPAMVK--RIm1 MA-----TSLLSPLLVAMLG--FLLHVHVARAGLE-HTCTLETRMQGAHPQGICGSKLPDIVHTVCQVMGRGY------Im2 MAL---TWPSSPPVLLTLLLSLLALQLCAVYGSYE-HTCTLATRSRGAHPSGICGRNLARIVSVLCTPRG--Y-------

A0A0B5ADV0|Con-Ins
A0A0B5A8P4|Con-Ins
A0A0B5AC86|Con-Ins
A0A0B5A7P2|Con-Ins
A0A0B5A8Q2|Con-Ins

Me1
G3
G3b
G1C
G1b

--SGSALKKRGRPSR-----------------RMKRR-----------------------DFLSALKTRVKR---------RNDAGKKRGRASP-----------------LWQRQ-----------------------GFLSMLKA--KR---------RNDAGKKRGRASP-----------------LWQRQ-----------------------GFLSMLKA--KR---------RNDAGKKRGRASP-----------------LWQRR-----------------------GSLSQLKARAKR---------RNDAGEKRGRASP-----------------LWQRR-----------------------GFLSKLKARAKR--------
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A0A0B5AC95|Con-Ins
A0A0B5ADU4|Con-Ins
A0A0B5ABD5|Con-Ins
A0A0B5AC90|Con-Ins
A0A0B5ABD9|Con-Ins
A0A0B5ADT3|Con-Ins
A0A0B5ABE4|Con-Ins
A0A0B5ABE6|Con-Ins
A0A0B5AC98|Con-Ins
A0A0B5A7N5|Con-Ins
A0A0B5A7N1|Con-Ins
A0A0B5ADT9|Con-Ins
A0A0B5A8Q6|Con-Ins
A0A0B5A7N8|Con-Ins
A0A0F7YYV0|ILP-1
P91797|MIP-7
Q9NDE7|MIP-1
P80090|MIP-3
P07223|MIP-1
P25289|MIP-2
P31241|MIP-5
A0A0B5A7M7|Con-Ins
A0A0B5A8P8|Con-Ins

G1a
T1
T3
T2
G2
G2b
Q1b
Q1
F1
F2C
F2b
F2
M1
Tx1

--RNDAGEKRGRASP-----------------LWQRR-----------------------GSLSKLKARAKR---------RNDAGKKRGRASP-----------------LWQRG-----------------------GSLSMLKARAKR---------RNDAGKKRGQASP-----------------LWQRG-----------------------GSLSMLKARAKR---------RNDAGKKRGQASP-----------------LWQRG-----------------------GSLSMLKARAKR---------TNDGGKKRRRASP-----------------LWKRR-----------------------RFLSMLKARAKR---------TNDGGKKRRRASP-----------------LRKRR-----------------------RFISMLKARAKR---------TDDARKKRGRASL-----------------LRKRR-----------------------GFLSMLKARAKR---------TDDARKKRGRASL-----------------LRKRR-----------------------GFLSMLKARAKR---------TG---KKRGRASP-----------------LRKRR-----------------------AFLSMLKARAKR---------TG---KKRGRASL-----------------LRKRR-----------------------AFLSMLKARAKR---------TG---KKRGRASL-----------------LRKRR-----------------------AFLSMLKARAKR---------TG---KKRGRASL-----------------LRKRR-----------------------AFLSMLKARAKR---------TNDARATTGRALS-----------------LSKRR-----------------------GFLSMLKRRGKR---------ANNARANTGRTSS-----------------LMKRR-----------------------GFLSLLKKRGKR---------ANNARAYTGRTSS-----------------LMKRR-----------------------GFLSLLKKRGKR-------RSVDNTFEKV-YSIPLSVLAELDLSDDDWGAYVSKKDIPYRSETNGLSGANFESSAFDKQLELPAMKSTTSQLFRILKLR
-----RFL---AKYMVKRD-TENVNDKLRGILLNKKE------------------------AFSYLTKR----------QAE-----------------PDEEDDAMSKIMISKKR------------------------ALSYLTKR---------------------------RNAETDLDDPLRNIKLSSES------------------------ALTYLTKR----------DAETGWLL---PETMVKRNAETDLDDPLRNIKLSSES------------------------ALTYLTKR----------DAETGWLL---PETMVKRNAQTDLDDPLRNIKLSSES------------------------ALTYLTKR----------Im1 --AGGQRQLRKRTSMIDSDDMEAEGGSRGGFLMSKRR------------------------ALSYLQKETNPL--VMAGY
Im2 --VSNWFTK--RSAP-NKPAETFVDQNLRGVLLNKRE------------------------ALSYLRPR-----------

A0A0B5ADV0|Con-Ins
A0A0B5A8P4|Con-Ins
A0A0B5AC86|Con-Ins
A0A0B5A7P2|Con-Ins
A0A0B5A8Q2|Con-Ins
A0A0B5AC95|Con-Ins
A0A0B5ADU4|Con-Ins
A0A0B5ABD5|Con-Ins
A0A0B5AC90|Con-Ins
A0A0B5ABD9|Con-Ins
A0A0B5ADT3|Con-Ins
A0A0B5ABE4|Con-Ins
A0A0B5ABE6|Con-Ins

Me1
G3
G3b
G1C
G1b
G1a
T1
T3
T2
G2
G2b
Q1b
Q1

KEGRSVKRSPTSGMSCECCKNSCDAEEILEYCPPLPSS---------------------NEAFFLQRD-GRGIVEVCCDNPCTVATLRTFCH--------------------------NEAFFLQRD-GRGIVEVCCDNPCTVATLMTFCH--------------------------NGAFHLPRD-GRGVVEHCCHRPCSNAEFKKYCS--------------------------NGAFHLPRD-GRGVVEHCCHRPCSNAEFRKYCG--------------------------NGAFHLPRD-GRGVVEHCCHRPCSNAEFKKYCG--------------------------NEAFHLQRA-HRGVVEHCCHRPCSNAEFKKFCG--------------------------NEAFHLQRA-HRGVVEHCCKRACSNAEFMQFCGNS------------------------NEAFHLQRA-HRGVVEHCCYRPCSNAEFKKFCG--------------------------TG--------YKGIACECCQHYCTDQEFINYCPPVTESSSSSSSAA-------------RG--------YQGIACECCQHYCTDQEFINYCPPVTESSSSSSSAV-------------NEASPLPRA-GRGIVCECCKNSCTYEEITEYCPPVTEGSG-------------------NEASPLPRA-GRGIVCECCKNSCTYEEITEYCPPVTEGSG--------------------
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A0A0B5AC98|Con-Ins
A0A0B5A7N5|Con-Ins
A0A0B5A7N1|Con-Ins
A0A0B5ADT9|Con-Ins
A0A0B5A8Q6|Con-Ins
A0A0B5A7N8|Con-Ins
A0A0F7YYV0|ILP-1
P91797|MIP-7
Q9NDE7|MIP-1
P80090|MIP-3
P07223|MIP-1
P25289|MIP-2
P31241|MIP-5
A0A0B5A7M7|Con-Ins
A0A0B5A8P8|Con-Ins

F1
F2C
F2b
F2
M1
Tx1

NEASPLQRS-GRGIVCECCKNHCNIEELTEYCPPVTEGSG-------------------NEASPLQRS-GRGIVCECCKNHCNIEELTEYCPPVTEGSG-------------------NEASPLQRS-GRGIVCECCKNHCNLEELTEYCPPVTEGSG-------------------NEASPLQRS-GRGIVCECCKNHCNIEELTEYCPPVTEGSG-------------------NEASPLQRA-GRGIVCECCKNHCTDEEFTEYCPHVTESG--------------------DEGSPLQRS-GRGIVCECCKHHCTKEEFTEYCH--------------------------DEGS-LQRS-GRGIVCECCKHHCTKEELTEYCH--------------------------GSRLKREVMAEPSLVCDCCYNECSVRKLATYC-----------------------------------EASGSITCECCFNQCRIFELAQYCRLPDHFFSRISRTGRSNSGHAQLEDNFS
--------ESRPSIVCECCFNQCTVQELLAYC-----------------------------------QGTTNIVCECCMKPCTLSELRQYCP----------------------------------QRTTNLVCECCFNYCTPDVVRKYCY----------------------------------QRTTNLVCECCYNVCTVDVFYEYCY--------------------------Im1 ERRGIQKRHGEQGITCECCYNHCSFRELVQYCN--------------------------Im2 EPRATRGTFGSQGITCECCFNQCTYYELLQYCN---------------------------

Figure 72- Alignment of gastropod insulin superfamily proteins. Sequences are from InterPro database (reviewed).
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